A trauma service: First of its kind in India
Paper read at All Indian Surgeons Conference, Delhi, India , December 1975.
Cytological diagnosis of hepatic dysfunction following liver transplantation (poster)
British Society of Gastroenterology, Cardiff, September 1986 (Abstract Gut 27:A1265, 1986).
Post-operative morbidity and mortality of liver transplantation
British Transplantation Society, Birmingham, April 1986.
Monitoring of Cyclosporine A in liver transplant patients
Cyclosporine A HPLC Workshop, University of Liverpool, September 1986.
Benefit of cadaveric organ transplantation using Cyclosporine A
Second International Conference on Surgery in the Tropics, Bombay, India, February 1987.
Liver transplantation: Our experience and results
Second International Conference on Surgery in the Tropics, Bombay, India, February 1987.
Symposium on organ transplantation. Second International Conference on Surgery in the Tropics. Bombay, India, February 1987.
Pharmacokinetic studies monitoring Cyclosporine by daily trough levels in liver transplant patients
British Transplantation Society, Belfast, April 1987.
Transperitoneal approach to upper urinary tract lesions and one-stage bilateral procedure
Midland Urology Club, West Midlands Surgical Society, November 1987.
Long-term results of cyclosporine renal transplantation from a single center
The Second International Congress on Cyclosporine. Washington, DC, November 1987.
Is elimination of Cyclosporine in bile dependent on liver graft functions and biliary drainage? The Second International Congress on Cyclosporine. Washington, DC, November 1987.
Is selective conversion from Cyclosporine to Azathioprine in cadaveric renal transplant better than elective conversion? British Transplantation Society, Newcastle Upon Tyne, April 1989.
Conversion of liver allograft recipients with Cyclosporine-related complications from Cyclosporine to FK 506
Symposium FK 506 IV Congress of the European Society for Organ Transplantation. Barcelona, Spain, October 31, 1989.
Early trials with FK 506 as primary treatment in liver transplantation
Symposium FK 506 IV Congress of the European Society for Organ Transplantation. Barcelona, Spain, October 31, 1989.
The side effects of FK 506 upon renal function after liver transplantation
Symposium FK 506 IV Congress of the European Society for Organ Transplantation. Barcelona, Spain, October 31, 1989.
FK 506 dosage in human organ transplantation
Symposium FK 506 IV Congress of the European Society for Organ Transplantation. Barcelona, Spain, October 31, 1989.
The side effects of the FK 506 in humans
Symposium FK 506 IV Congress of the European Society for Organ Transplantation, Barcelona, Spain, October 31, 1989.
Gastroenterology and metabolic problems associated with immunosuppression with either Cyclosporine or FK 506 in liver transplantation
Symposium FK 506 IV Congress for the European Society for Organ Transplantation. Barcelona, Spain, October 31, 1989.
Oral glucose tolerance test in liver recipients treated with FK 506
Symposium FK 506 IV Congress of the European Society for Organ Transplantation. Barcelona, Spain, October 31, 1989.
A cost comparison of liver transplantation with FK 506 or Cyclosporine as the primary immunosuppressive agent
Symposium FK 506 IV Congress of the European Society for Organ Transplantation. Barcelona, Spain, October 31, 1989.
Pharmacokinetics of FK 506 pre-clinical and clinical studies
Symposium FK 506 IV Congress of the European Society for Organ Transplantation. Barcelona, Spain, October 31, 1989.
Effect of hepatic dysfunction and T-tube clamping of FK 506 pharmacokinetics and trough concentrations
Symposium FK 506 IV Congress of the European Society for Organ Transplantation. Barcelona, Spain, October 31, 1989.
Cyclosporine measurement by FPIA, PcRIA, and HPLC following liver transplantation. Cyclosporine Therapeutic Drug Monitoring. Hawks Bay, Florida, January 1990
Liver transplantation in Birmingham. Use of Cyclosporine: Clinical correlation with drug monitoring. Cyclosporine Therapeutic Drug Monitoring. Hawks Bay, Florida, January 1990
Use of FK 506 in the treatment of chronic liver allograft rejection
American Society of Surgical Transplantation. Chicago, IL, 1990.
Venkataramanan, AB Jain, VS Warty, K Abu-Elmagd, H Furukawa, O Imventarza, JJ Fung, S Todo, TE Starzl. Pharmacokinetics of FK 506 following oral administration. A comparison of FK 506 and Cyclosporine
XIII International Congress of the Transplantation Society, San Francisco, August 1990.
Conversion of liver allograft recipients from Cyclosporine to FK 506-based immunosuppression: Benefits and pitfalls
XIII International Congress of the Transplantation Society, San Francisco, CA, August 1990.
Todo, JJ Fung, A Tzakis, AJ Demetris, AB Jain, M Alessiani, S Takaya, TE Starzl. 110 consecutive primary orthotopic liver transplantation under FK 506 in adults
XIII International Congress of the Transplantation Society, San Francisco, CA, August 1990.
Alessiani, S Kusne, M Martin, AB Jain, K Abu-Elmagd, J Moser, JJ Fung, TE Starzl. Infection in adult liver transplant patients under FK 506 immunosuppression
XIII International Congress of the Transplantation Society, San Francisco, CA, August 1990.
The question of FK 506 nephrotoxicity
XIII International Congress of the Transplantation Society, San Francisco, CA, August 1990.
Early infections in kidney transplant recipients under FK 506
XIII International Congress of the Transplantation Society, San Francisco, CA, August 1990.
A Zeevi, G Eiras, C Kaufman, M Alessiani, AJ Demetris, K Abu-Elmagd, AB Jain, V Warty, R Venkataramanan, G Burckart, TE Starzl, S Todo, JJ Fung, R Duquesnoy, XIII International Congress of the Transplantation Society, San Francisco, CA, August 1990.
Current status on FK 506 in liver transplantation
First Symposium of the International Society for Peri-Operative Care in Liver Transplantation. Pittsburgh, PA, September 1990.
An overview on clinical organ transplantation under FK 506
Proceedings of the 22nd International Course of Transplantation and Clinic Immunology, Lyon, France, May 1990.
Preliminary results of prospective randomized trial of FK 506 versus Cyclosporine (CyA) in orthotopic liver transplantation
British Transplantation Society, Cambridge, April 1991.
Alessiani, C Ricordi, JJ Fung, K Abu-Elmagd, Jain AB, C. Scotti, A Pinna, U Cillo, G Carrieri, TE Starzl. USO Clinico Del. FK 506 NEL Trapianto di Fegato 1991
Intravenous, oral pharmacokinetics and dosing of FK 506 in small bowel transplant patients
Second International Symposium on Small Bowel Transplantation. Toronto, Ontario, Canada, October 1991.
Infectious complications after human small bowel transplantation
Second International Symposium on Small Bowel Transplantation, Toronto, Ontario, Canada, October 1991.
Correlation of episodes of rejections with FK dosage and FK level following primary orthotopic liver transplantation
First International Congress on FK 506. Pittsburgh, PA, August 1991.
Comparative study of Cyclosporine and FK 506 dosage requirement in adult and pediatric orthotopic liver transplantation
First International Congress on FK 506. Pittsburgh, PA, August 1991.
Pharmacokinetics of Cyclosporine and nephrotoxicity in orthotopic liver transplant patients rescued with FK 506
First International Congress on FK 506. Pittsburgh, PA, August 1991.
Changes in quality of life following conversion from CyA to FK 506 in orthotopic liver transplant patients
First International Congress on FK 506. Pittsburgh, PA, August 1991.
Re-transplantation of the liver: A comparison of FK 506 Cyclosporine-treated patients
First International Congress on FK 506. Pittsburgh, PA, August 1991.
The incidence of CMV infection during a randomized trial comparing cyclosporine to FK 506 immunosuppression in liver transplantation
First International Congress on FK 506. Pittsburgh, PA, August 1991.
The incidence of infections during a randomized trial comparing Cyclosporine to FK 506 immunosuppression in liver transplantation
First International Congress on FK 506. Pittsburgh, PA, August 1991.
Acute hemolytic anemia in liver and bone marrow transplant patients under FK 506 therapy
First International Congress on FK 506. Pittsburgh, PA, August 1991.
The use of FK 506 in primary liver transplantation
First International Congress on FK 506. Pittsburgh, PA, August 1991.
The strategy of FK 506 therapy in liver transplant patients: The effect of graft function
First International Congress on FK 506. Pittsburgh, PA, August 1991.K Abu-Elmagd, JJ Fung, R Daviam, AB Jain, M Alessiani, S Takaya, R Venkataramanan, VS Warty, W Shannon, A Tzakis, S Todo, TE Starzl. Four-hour versus 24-hour intravenous infusion of FK 506 in primary liver recipients. First International Congress on FK 506. Pittsburgh, PA, August 1991.
Serial monitoring of immunologic function and phenotype of lymphocytes in the blood of transplanted patients randomized to Cyclosporine A or FK 506
First International Congress on FK 506. Pittsburgh, PA, August 1991.
FK 506 in clinical kidney transplantation
First International Congress on FK 506. Pittsburgh, PA, August 1991.
Re-transplantation of the liver: A comparison of FK 506 and Cyclosporine-treated patients
First International Congress on FK 506. Pittsburgh, PA, August 1991.
Renal transplantation under FK 506 in patients with previous renal failure due to hemolytic uremic syndrome (HUS)
First International Congress on FK 506. Pittsburgh, PA, August 1991.
Pharmacokinetics of FK 506 in liver transplant patients
First International Congress on FK 506. Pittsburgh, PA, August 1991.
First International Congress on FK 506. Pittsburgh, PA, August 1991.
Renal function in liver transplant patients under FK 506
First International Congress on FK 506. Pittsburgh, PA, August 1991.
Neurotoxicity of FK 506 in liver and thoracic organ transplant recipients
First International Congress on FK 506. Pittsburgh, PA, August 1991.
Treatment of chronic graft-versus-host disease (GVHD) following bone marrow transplantation with FK 506
First International Congress on FK 506. Pittsburgh, PA, August 1991.
FK 506 for the treatment of scleritis, uveitis, keratitis, and hearing loss. A case report of Cogan’s syndrome
First International Congress on FK 506. Pittsburgh, PA, August 1991.
Efficacy of FK 506 in the treatment of pyoderma gangrenosum
First International Congress on FK 506. Pittsburgh, PA, August 1991.
Side effects of FK 506 compared to Cyclosporine in a prospective randomized trial of orthotopic liver transplantation
First International Congress on FK 506. Pittsburgh, PA, August 1991.
Renal function after conversion from Cyclosporine to FK 506 in liver transplant patients
First International Congress on FK 506. Pittsburgh, PA, August 1991.
Conversion of liver allograft recipients from Cyclosporine to KF 506 immunosuppressive therapy
First International Congress on FK 506. Pittsburgh, PA, August 1991.
A prospective randomized trial comparing Cyclosporine versus FK 506 in primary liver transplantation
Proceedings of the 5th International Congress of the European Society of Organ Transplantation. Maastricht, The Netherlands, October 6-10, 1991.
USO Clinico Del—FK 506 Nel Trapianto Di Fegato
In All Trapianto Oggi—Proceedings of the 21st Congress of the Italian Society of Organ Transplantation. Ed. Monduzzi: 611-615, 1991.
The renal consequences of orthotopic liver transplant rescue therapy with FK 506: three year’s follow up
American Society of Transplant Physicians 11th Annual Scientific Meeting, 1992.
Incidence and severity of liver allograft rejection following institution of Alpha Interferon for treatment of viral hepatitis in liver transplant recipients
94th Annual Meeting of the American Gastroenterological Association, May 1993, Boston, MA, (Abstract) Gastroenterology 104(4)2, A922, 1993.
Pregnancy in liver transplant patients under FK 506 regimen
12th American Society of Transplant Physicians. Houston, TX, May 1993.
Three-year follow up of adults receiving primary orthotopic liver transplantation under FK 506
Second Congress of the International Liver Transplantation Society. Toronto, Canada, October 1993.
Long-term effects of FK 506 following conversion from Cyclosporine to FK 506 for chronic rejection in liver transplant recipient
44th American Association for the Study of Liver Disease. Chicago, IL, November 1993. Abstract: Hepatology 18(4):2, 74A, 1993.
FK 506 in small bowel transplant recipients: Pharmacokinetics and dosing aspects
Third International Symposium on Small Bowel Transplantation. Paris, France, November 1993.
Interferon Alpha 2B for Non A, Non B, and Non C hepatitis in liver allograft recipients. Clinical and Pathological Outcome
45th American Association for the Study of Liver Diseases. Chicago, IL, November 11-15, 1994. Abstract: Hepatology 20(4):2, 13A, October 1994.
Adult primary orthotopic liver transplantation under FK 506: four-year follow up
45th American Association for the Study of Liver Diseases. Chicago, IL, November 11-15, 1994. Abstract: Hepatology 20(4):2, 137A, October 1994.
Clinical outcome and pathological correlation following Interferon Alpha 2B treatment of recurrent hepatitis B and hepatitis C in orthtopic liver allograft recipients
45th American Association for the Study of Liver Diseases. Chicago, IL, November 11-15, 1994. Abstract: Hepatology 20(4):2, 130A, October 1994.
High dose FK506 requirement in transplant patients
XVth World Congress of the Transplantation Society. Kyoto, Japan, August 28 – September 2, 1994.
Conversion from FK 506 to Cyclosporine due to FK 506 toxicity following orthotopic liver transplantation
American Society of Transplant Physicians 13th Annual Scientific Meeting, Chicago, IL, May 16-18, 1994.
Recurrent or de novo B and C hepatitis influence the development of vanishing bile duct syndrome after liver transplantation
XVth World Congress of the Transplantation Society, Kyoto, Japan, August 28 – September 2, 1994.
Pediatric primary liver transplantation under FK 506 immunosuppression: Four-years’ experience
XVth World Congress of the Transplantation Society. Kyoto, Japan, August 28 – September 2, 1994.
One thousand consecutive primary liver transplantations under FK 506: Survival and adverse events
XVth World Congress of the Transplantation Society. Kyoto, Japan , August 28 – September 2, 1994.
The renal consequences of orthotopic liver transplant resume therapy with FK 506: Three-year follow up
American Society of Transplant Physicians 13th Annual Scientific Meeting. Chicago, IL, May 16-18, 1994.
Long-term clinical and histopathological impact of Alpha Interferon 2B treatment in liver allograft recipients for recurrent hepatitis C viral Disease
American Association for the Study of Liver Diseases: Liver transplantation for chronic viral hepatitis. Reston, VA, March 1995.
Morbidity other than rejection with primary liver transplantation: 1,000 consecutive cases
American Society of Transplant Physician’s 14th Annual Scientific Meeting. Chicago, IL, May 14-17, 1995.
Pediatric primary orthotopic liver transplantation under tacrolimus
First International Liver Transplantation Society and Liver Intensive Care Group Europe. London, United Kingdom, September 27-30, 1995. Abstract: Liver Transplantation and Surgery 1(6): 425, November 1995.
Conversion from Cyclosporine to tacrolimus in pediatric liver transplant recipients
First International Liver Transplantation Society and Liver Intensive Care Group Europe. London, United Kingdom, September 27-30, 1995. Abstract: Liver Transplantation and Surgery 1(6):425, November 1995.
Long-term outcome of conversion from Cyclosporine to tacrolimus for chronic liver a llograft rejection: Actual more than five-years’ follow up
First International Liver Transplantation Society and Liver Intensive Care Group Europe. London, United Kingdom, September 27-30, 1995. Abstract: Liver Transplantation and Surgery 1(6):425, November 1995.
Adult primary liver transplantation under tacrolimus: More than five- years’ actual follow up
First International Liver Transplantation Society and Liver Intensive Care Group Europe. London, United Kingdom, September 27-30, 1995. Abstract: Liver Transplantation and Surgery 1(6):425, November 1995.
Liver transplantation in alcoholic and non-alcoholic cirrhosis: Survival according to UNOS status, sobriety and rehabilitation
The International Liver Transplantation Society and Liver Intensive Care Group Europe. London, United Kingdom, September 27-30, 1995, Abstract: Liver Transplantation and Surgery 1(6):425, November 1995.
Does trans-jugular intrahepatic portosystemic shunt (TIPS) correct thrombocytopenia associated with liver cirrhosis? The International Liver Transplantation Society and Liver Intensive Care Group Europe. September 27- 30, 1995. London, United Kingdom, September 27-30, 1995. Abstract: Liver Transplantation and Surgery 1(6):425, November 1995.
Comparative study of pharmacokinetic profile following intravenous infusion of tacrolimus in pediatric and adult liver transplant recipients
The American Association for the Study of Liver Diseases. Chicago, IL, November 3-7, 1995. Abstract: Hepatology 22(4):2: 143A, October 1995.
Pharmacokinetics of tacrolimus in transplant patients
Proceedings of the 4th International Congress of Therapeutic Drug Monitoring and Clinical Toxicology, 1995.
Comparison between whole-blood tacrolimus by Abbott, Inc. and plasma tacrolimus by enzyme-linked immunoassay
Proceedings of the 4th International Congress of Therapeutic Drug Monitoring and Clinical Toxicology, 1995.
Immunosuppression: Novel agents
Pittsburgh Transplantation Institute Conference 1996. Holiday Inn Select at University Center, Pittsburgh, PA, April 11-13, 1996.
Incidence and causes of gastrointestinal bleeding in adults following liver transplantation
96th Annual Meeting of the American Gastroenterological Association. San Francisco, CA, May 19-22, 1996.
Pharmacokinetics of Mycophenolate Mofetil and its potential interaction with tacrolimus
American Society of Transplant Surgeons 22nd Annual Scientific Meeting. Dallas, TX, May 29-31, 1996.
De novo non-lymphoid malignancies, following 1000 consecutive liver transplantation under tacrolimus
American Society of Transplant Physicians 15th Annual Meeting. Dallas, TX, May 26-30, 1996.
Tacrolimus dosing in stable liver transplant (OLTx) recipients correlates with phenotypic CYP34A enzyme activity but not leukocyte CYP3A4 in RNA expression
American Society of Transplant Physicians 15th Annual Meeting. Dallas, TX, May 26-30, 1996.
Impact of positive crossmatch due to IgG versus IgM antibodies on the outcome of primary liver transplantation under tacrolimus
American Society of Transplant Physicians 15th Annual Meeting. Dallas, TX, May 26-30, 1996.
Conversion of pediatric liver allograft recipients from Cyclosporine to tacrolimus-based immunosuppression
The 2nd International Congress on Pediatric Transplantation. Paris, France, August 22-24, 1996. Abstract: Pediatric Nephrology 10 C31-C94, 1996.
Cardiac changes at autopsy in pediatric liver transplant recipients under tacrolimus
The 2nd International Congress on Pediatric Transplantation. Paris, France, August 22-24, 1996. Abstract: Pediatric Nephrology 10:C31-C94, 1996.
Reversible myocardial hypertrophy after liver and liver-small bowel transplantation in children under Tacrolimus (FK 506) immunosuppression
The 2nd International Congress on Pediatric Transplantation. Paris, France, August 22-24, 1996. Abstract: Pediatric Nephrology 10:C31-C94, 1996.
Primary liver transplantation in children under tacrolimus
The 2nd International Congress on Pediatric Transplantation. Paris, France, August 22-24, 1996. Abstract: Pediatric Nephrology 10:C31-C94, 1996.
Liver re-transplantation in children: Study of 184 cases
The 2nd International Congress on Pediatric Transplantation. Paris, France, August 22-24, 1996. Abstract: Pediatric Nephrology 10:C31-C94, 1996.
Cardiac changes at autopsy in adult liver transplant receipients under tacrolimus
XVI International Congress of the Transplantation Society. Barcelona, Spain, August 25-30, 1996.
Tacrolimus dosing in stable liver transplant (OLTx) recipients correlates with phenotypic CYP3A4 enzyme activity but not leukocyte CYP3A4 mRN expression
American College of Clinical Pharmacy Annual Meeting, 1996.
More than six years’ actual follow up: Primary adult liver transplantation under tacrolimus
The 47th American Association for the Study of Liver Disease 1996. Abstract: Hepatology 24(4):181A.
More than six years’ actual follow up conversion from Cyclosporine to tacrolimus for chronic liver allograft rejection
The 47th American Association for the Study of Liver Disease 1996. Abstract: Hepatology 24(4):181A.
Conversion from Cyclosporine to Neoral in stable liver transplant recipients
The 47th American Association for the Study of Liver Disease 1996. Abstract: Hepatology 24(4):181A.
Prospective randomized trial of tacrolimus and Prednisone versus tacrolimus, Prednisone versus tacrolimus, Prednisone and Mycophenolate Mofetil in primary adult liver transplant recipients
Oral presentation at the Joint American Society of Transplant Physicians 16th and Surgeons 23rd. Chicago, IL, May 1997.
Long-term effect of Interferon Alpha for HCV infection post-liver transplantation: Actual five-to-seven-years’ follow up
American Association for the Study of Liver Disease. Virginia, June 1997.
Use of Mycophenolate Mofetil in the pediatric population after liver and intestinal transplantation
16th American Society of Transplant Physicians. Chicago, IL, May 10-14, 1997.
Use of Mycophenolate Mofetil in the pediatric population after intestinal transplantation
Fifth International Symposium of Intestinal Transplantation. Cambridge, United Kingdom, July 30 – August 2, 1997.
Use of Mycophenolate Mofetil in the pediatric population after liver and intestinal transplantation
Fourth Congress of the International Liver Transplantation Society. Seattle, WA, October 15-17, 1997. Abstract: Liver Transplantation and Surgery 3(5):C-78(189), 1997.
Adolescent noncompliance following liver transplantation
Fourth Congress of the Liver Transplantation Society. Seattle, WA, October 15-17, 1997. Abstract: Liver Transplantation and Surgery 3(5):C-77 (188), 1997.
Prospective randomized trial of tacrolimus and Prednisone versus tacrolimus, Prednisone and Mycophenolate Mofetil in primary adult liver transplant recipients
Fourth Congress of the Liver Transplantation Society’s Plenary Session. Seattle, WA, October 15-17, 1997. Abstract: Liver Transplantation and Surgery 3(5):C-55(70), 1997.
More than seven years’ actual follow up: Primary adult liver transplantation under tacrolimus
Fourth Congress of the International Liver Transplantation Society. Seattle, WA, October 15-17, 1997. Abstract: Liver Transplantation and Surgery 3(5):C-71(162), 1997.
Chronic rejection following primary adult liver transplantation under tacrolimus
48th American Association for the Study of Liver Diseases. Chicago, IL, November 7-11, 1997. Abstract: Hepatology 29(4):2; 343-A, 1997. Abstract #859.
Clinical significance of elevated serum alfa-feto protein among patients with end-stage liver disease
48th American Association for the Study of Liver Diseases. Chicago, IL, November 7-11, 1997. Abstract: Hepatology 29(4):2; 171A, 1997. Abstract #171.
Use of Mycophenolate Mofetil for tacrolimus-related chronic nephrotixicity in liver transplantation recipients
48th American Association for the Study of Liver Diseases. Chicago, IL, November 7-11, 1997. Abstract: Hepatology 29(4)2; 235A, 1997. Abstract #429.
Long-term use of tacrolimus in liver transplant recipients
The First International Congress on Immunosuppression. Orlando, FL, December 10-13, 1997.
Conversion from tacrolimus to Neoral in adult liver transplant patients
The First International Congress on Immunosuppression. Orlando, FL, December 10-13, 1997.
Adult primary liver transplantation: Prospective randomized trial of tacrolimus and Mycophenolate Mofetil
The First International Congress on Immunosuppression. Orlando, December 10-13, 1997.
Use of Neoral for neurological complications following primary adult liver transplantation under tacrolimus
New Dimensions in Transplantation. Florence, Italy, February 16-19, 1998.
A prospective study on conversion from Cyclosporin to Neoral in stable adult liver transplant recipients
New Dimensions in Transplantation. Florence, Italy, February 16-19, 1998.
Adult primary liver transplantation: Prospective randomized trial of tacrolimus and steroid versus tacrolimus, steroid, and Mycophenolate Mofetil
American Society of Transplant Surgeons 24th Annual Meeting. Chicago, IL, May 13-15, 1998. Abstract: Transplantation 66(6): S2, 1998.
Primary liver transplantation under tacrolimus in infants, children, adults and seniors: 1000 consecutive patients from single center with five-to-eight years’ actual follow up
American Society of Transplant Surgeons 24th Annual Meeting. Chicago, IL, May 13-15, 1998. Abstract: Transplantation 66(6):S43(172), 1998.
Incidence of end-stage renal failutre amongst long-term survival of primary liver transplant recipients under tacrolimus: adults and children
American Society of Transplant Physicians’ 17th Annual Scientific Meeting, Chicago, IL, May 9-13, 1998.
Cytomegalovirus infection in liver transplant recipients: Detection of early antigenemia in peripheral blood leukocytes and pre-emptive therapy
American Society of Transplant Surgeons’ 19th Annual Scientific Meeting, Chicago, IL, May 9-13, 1998.
Conversion of pediatric liver allograft recipients from Cyclosporine to tacrolimus-based immunosuppression: Four-to-eight years’ follow up
American Society of Transplant Physicians’ 17th Annual Scientific meeting, Chicago, IL, May 9-13, 1998.
Primary liver transplantation in children under tacrolimus: Three-to-eight years’ actual follow up
American Society of Transplant Physicians’ 17th Annual Scientific Meeting, Chicago, IL, May 9-13, 1998.
Noncompliance after pediatric liver transplantation
American Society of Transplantation Physician’s 17th Annual Scientific Meeting, Chicago, IL, May 9-13, 1998.
Kidney transplantation for end-stage renal failure in liver transplant recipients with hepatitis C viral infection
American Society of Transplant Physicians’ 17th Annual Scientific Meeting, Chicago, IL, May 9-13, 1998.
Hepatitis C-related glomerulonephritis: A growing cause of renal failure after liver transplantation
American Society of Transplant Physicians’ 17th Annual Scientific Meeting, Chicago, IL, May 9-13, 1998.
Conversion of pediatric liver allograft recipients from Cyclosporin to tacrolimus-based immunosuppression: Four-to-eight years’ follow up
The 1998 Transplantation Society’s XVII World Congress. Montreal, Canada, July 12-17, 1998.
Primary liver transplantation in children under tacrolimus: Three-to-eight years’ actual follow up
The 1998 Transplantation Society’s XVII World Congress. Montreal, Canada, July 12-17, 1998.
Indications and results of hepatic retransplantation in children receiving primary tacrolimus therapy
The 1998 Transplantation Society’s XVII World Congress. Montreal, Canada, July 12-17, 1998.
Pre-transplant risk factors and long-term liver allograft outcomes in children receiving primary tacrolimus therapy
The 1998 Transplantation Society’s XVII World Congress. Montreal, Canada, July 12-17, 1998.
Noncompliance after pediatric liver transplantation
The 1998 Transplantation Society’s XVII World Congress. Montreal, Canada, July 12-17, 1998.
Primary liver transplantation under tacrolimus in infants, children, adults and seniors: 1000 consecutive patients from single center with five-to-eight years’ actual follow up
The 1998 Transplantation Society’s XVII World Congress. Montreal, Canada, July 12-17, 1998.
Adult primary liver transplantation: Prospective randomized trial of tacrolimus and steroid versus tacrolimus, steroid and Mycophenolate Mofetil
The 1998 Transplantation Society’s XVII World Congress. Montreal, Canada, July 12-17, 1998.
Kidney transplantation for end-stage renal failure in liver transplantation recipients carriers of hepatitis C virus
The 1998 Transplantation Society’s XVII World Congress. Montreal, Canada, July 12-17, 1998.
P-Glycoprotein (p-gp) is responsible for drug elimination in peripheral T-cells from solid organ and stem cell transplantation recipients
The 1998 Transplantation Society’s XVII World Congress. Montreal, Canada, July 12-17, 1998.
Use of Mycophenolate Mofetil in the pediatric population after liver and intestinal transplantation
Third International Congress on Pediatric Transplantation, 1998. Abstract: Ped Transplantation 174(2) 1998. Abstract # 175.
Liver transplantation today
First International Workshop (Neurological Problems and Liver Transplantation). Bologna, Italy, May 8, 1998 .
Conversion of pediatric liver allograft recipients from Cyclosporine in tacrolimus-based immunosuppression: Four-to-eight years’ follow up
The International Congress on Pediatric Transplantation, 1998. Abstract: Ped Transplantation 75(2), 1998. Abstract #177.
Noncompliance after pediatric liver transplantation: 2(1);78, 1998
Abstract: Ped Transplantation 78(2), 1998. Abstract #192.
Primary liver transplantation in children under tacrolimus: Three-to-eight years’ actual follow up
Third International Congress on Pediatric Transplantation. Abstract: Ped Transplantation 2(1); 75, 1998.
Indications and results of hepatic retransplantation in children receivingprimary tacrolimus therapy
Third International Congress on Pediatric Transplantation: Ped Transplantation 183(2), 1998. Abstract #181.
Clinical significance of elevated serum alpha feto protein among patients with end-stage liver disease
The Seventh Annual International Transplant Nurses Society Symposium and General Assembly. Portland, OR, September 10-12, 1998.
Prospective study of pregnancy following liver transplantation under tacrolimus
The Seventh Annual International Transplant Nurses Society Symposium and General Assembly. Portland, OR, September 10-12, 1998.
Conversion from Cyclosporine to Neoral in stable adult liver transplant recipients
The Seventh Annual International Transplant Nurses Society Symposium and General Assembly. Portland, OR, September 10-12, 1998.
Primary liver transplantation under tacrolimus in infants, children, adults and seniors: 1000 consecutive cases; mean follow up 76 months
The Seventh Annual International Transplant Nurses Society Symposium and General Assembly. Portland, OR, September 10-12, 1998.
Prospective randomized trial of tacrolimus and steroid versus tacrolimus, steroid and Mycophenolate Mofetil in primary liver transplant
The Seventh Annual International Transplant Nurses Society Symposium and General Assembly. Portland, OR, September 10-12, 1998.
Conversion of pediatric liver allograft recipients from Cyclosporin to tacrolimus-based immunosuppression: Four-to-eight years’ follow up
The Seventh Annual International Transplant Nurses Society Symposium and General Assembly. Portland, OR, September 10-12, 1998.
Primary liver transplantation in children under tacrolimus: Three-to-eight years’ actual follow up
The Seventh Annual International Transplant Nurses Society Symposium and General Assembly. Portland, OR , September 10-12, 1998.
Comparative incidence of de novo nonlymphoid malignancies following liver transplantation under tacrolimus using surveillance pedemiologic end-result data
The Seventh Annual International Transplant Nurses Society Symposium and General Assembly. Portland, OR, September 10-12, 1998.
Cytomegalovirus infection in liver transplant recipients: Detection of early antigenemia (p-g65) in peripheral blood leukocytes and pre-emptive therapy
The Seventh Annual International Transplant Nurses Society Symposium and General Assembly. Portland, OR, September 10-12, 1998.
Use of neural for post-liver transplant neurological complication under tacrolimus
The Seventh Annual International Transplant Nurses Society Symposium and General Assembly. Portland, OR, September 10-12, 1998.
Incidence of end-stage renal failure amongst long-term survival of primary liver transplant recipients under tacrolimus: adults and children
The Seventh Annual International Transplant Nurses Society Symposium and General Assembly. Portland, OR, September 10-12, 1998.
Prospective randomized trial of tacrolimus and steroid versus tacrolimus, steroid versus tacrolimus, steroid and Mycophenolate Mofetil in primary adult liver transplantation
49th American Association for the Study of Liver Diseases and International Association for the Study of the Liver. Chicago, IL, November 4-10, 1998. Abstract: Hepatology 28(4)2; 221A, 1998. Abstract #233.
Long-term impact of positive crossmatch due to IgG versus IgM antibodies in primary liver transplantation under tacrolimus
49th American Association for the Study of Liver diseases and International Association for the Study of the Liver. Chicago, IL, November 4-10, 1998. Abstract: Hepatology 28(4);2,351A, 1998. Abstract #756.
Primary liver transplant under tacrolimus in infants, children, adults and seniors: 1000 consecutive cases: mean follow up seven years
49th American Association for the Study of Liver Diseases and International Association for the Study of the Liver. Chicago, IL, November 4-10, 1998. Abstract: Hepatology 28(4);2, 351A, 1998. Abstract #755.
Conversion of pediatric liver allograft recipients from Cyclosporin to tacrolimus-based immunosuppression: Mean seven years’ actual follow up
49th American Association for the Study of Liver Diseases and International Association for the Study of the Liver. Chicago, IL, November 4-10, 1998. Abstract: Hepatology 28(4);2, 351A, 1998. Abstract #754.
Primary liver transplantation in children under tacrolimus and Cyclosporine: Comparative study
49th American Association for the Study of Liver Diseases and International Association for the Study of the Liver. Chicago, IL, November 4-10, 1998. Abstract: Hepatology 28(4);2, 351A, 1998. Abstract #753.
Conversion from Cyclosporine to tacrolimus for chronic liver allograft rejection: More than eight years’ actual follow up
49th American Association for the Study of Liver Diseases and International Association for the Study of the Liver. Chicago, IL, November 4-10, 1998. Abstract: Hepatology 28(4);2, 221A, 1998. Abstract #233.
Plasma protein bindings of Mycophenolic acid affects its clearance
49th American Association for the Study of Liver Diseases and International Association for the Study of the Liver. Chicago, IL, November 4-10, 1998. Abstract: Hepatology 28(4);2, 271A, 1998. Abstract #434.
Long-term results of liver transplantation for alcoholic-related liver disease under tacrolimus
49th American Association for the Study of Liver Diseases and International Association for the Study of Liver Diseases. Chicago, IL, November 4-10, 1998. Abstract: Hepatology 28(4)2:350A, 1998. Abstract: #752.
Prospective randomized trial of tacrolimus and steroids versus tacrolimus, steroids and mycophenolate mofetil in primary adult liver transplantation
49th American Association for the Study of Liver Diseases and International Association for the Study of Liver Diseases. Chicago, IL, November 4-10, 1998. Abstract: Hepatology 28(4)2:241A, 1998. Abstract: #313.
1000 consecutive primary liver transplants under tacrolimus: Story of success and failure with mean follow up of seven years’
119th American Surgical Association. San Diego, CA, April 1999.
Comparative incidence of de novo nonlymphoid malignancies following liver transplantation under tacrolimus using surveillance epidemiologic end-result data
2nd International Transplant Coordinator’s Society Meeting, Maastricht, The Netherlands. April 1999.
Cytomegalovirus infection in liver transplant recipients: Detection of early antigenemia (p-g65) in peripheral blood leukocytes and pre-emptive therapy
2nd International Transplant Coordinator’s Society Meeting, Maastricht, The Netherlands. April 1999.
Long-term results of liver transplantation for alcoholic-related liver disease under tacrolimus
2nd International Transplant Coordinator’s Society Meeting, Maastricht, The Netherlands. April 1999.
Use of neural for post-liver transplant neurological complication under tacrolimus
2nd International Transplant Coordinator’s Society Meeting, Maastricht, The Netherlands. April 1999.
Incidence of end-stage renal failure amongst long-term survival of primary liver transplant recipients under tacrolimus: Adults and children. M Funovits, AB Jain, I Hamad, B Yelochan, JJ Fung, K Nestler, C Hartner, S Kusne. Cytomegalovirus infection in liver transplant recipients: Detection of early antigenemia (p-g65) in peripheral blood leukocytes and pre-emptive therapy
International Transplant Coordinator’s Society Meeting, Maastricht, The Netherlands. April 1999.
Prospective randomized trial of tacrolimus and steroid versus tacrolimus, steroid and Mycophenolate Mofetil in primary liver transplant. M Funovits, AB Jain, I Hamad, B Yelochan, JJ Fung, K Nestler, C Hartner, S Kusne. Cytomegalovirus infection in liver transplant recipients: Detection of early antigenemia (p-g65) in peripheral blood leukocytes and pre-emptive therapy
International Transplant Coordinator’s Society Meeting, Maastricht, The Netherlands. April 1999.
Conversion from Cyclosporine to tacrolimus for chronic liver allograft rejection: More than eight years’ actual follow up. M Funovits, AB Jain, I Hamad, B Yelochan, JJ Fung, K Nestler, C Hartner, S Kusne. Cytomegalovirus infection in liver transplant recipients: Detection of early antigenemia (p-g65) in peripheral blood leukocytes and pre-emptive therapy
International Transplant Coordinator’s Society Meeting, Maastricht, The Netherlands. April 1999
Long-term impact of positive crossmatch due to IgG versus IgM antibodies in primary liver transplantation under tacrolimus in adults and children. M Funovits, AB Jain, I Hamad, B Yelochan, JJ Fung, K Nestler, C Hartner, S Kusne. Cytomegalovirus infection in liver transplant recipients: Detection of early antigenemia (p-g65) in peripheral blood leukocytes and pre-emptive therapy
International Transplant Coordinator’s Society Meeting, Maastricht, The Netherlands. April 1999.
Primary liver transplant under tacrolimus: 1000 consecutive cases: mean follow up seven years’
Prospective study of pregnancy following liver transplantation under tacrolimus
International Transplant Coordinator’s Society Meeting, Maastricht, The Netherlands. April 1999.
Long-term outcome of hepatitis C viral infection in primary adult liver transplant recipients compared to non-HCV under tacrolimus
8th Annual Meeting of the American Society of Transplantation (AST), May 15-19, 1999. Chicago, IL, 1999. Abstract: Transplantation 67(7):S15, 1999.
Conversion from tacrolimus to Cyclosporine A following primary liver transplantation under tacrolimus
18th Annual Meeting of the American Society of Transplantation (AST), May 15-19, 1999. Chicago, IL, 1999. Abstract: Transplantation 67(7):S32, 1999.
Drug metabolism in older OLTx patients: Effects of donor and recipient age
18th Annual Meeting of the American Society of Transplantation (AST), May 15-19, 1999. Chicago, IL, 1999. Abstract: Transplantation 67(7):S145, 1999.
More than six years’ actual follow up: Conversion from Cyclosporine to tacrolimus for chronic liver allograft rejection
18th Annual Meeting of the American Society of Transplantation (AST), May 15-19, 1999. Chicago, IL, 1999. Abstract: Transplantation 67(7):S197, 1999.
Long-term results of liver transplantation for alcoholic-related liver disease under tacrolimus
18th Annual Meeting of the American Society of Transplantation (AST), May 15-19, 1999. Chicago, IL, 1999. Abstract: Transplantation 67(7):S765, 1999.
Long-term impact of positive crossmatch due to IgG versus IgM antibodies in primary liver transplantation under tacrolimus
18th Annual Meeting of the American Society of Transplantation (AST), May 15-19, 1999. Chicago, IL, 1999. Abstract: Transplantation 67(7):S198, 1999.
Acute renal failure requiring dialysis in liver transplant recipients under tacrolimus, Prednisone versus tacrolimus, Prednisone and Cellcept
18th Annual Meeting of the American Society of Transplantation (AST), May 15-19, 1999. Chicago, IL, 1999. Abstract: Transplantation 67(7):S201, 1999.
Long-term effect of Interferon-Alpha for HCV infection in post-liver transplantation: Actual seven-to-nine years’ follow up
18th Annual Meeting of the American Society of Transplantation (AST), May 15-19, 1999. Chicago, IL, 1999. Abstract: Transplantation 67(7):S201, 1999.
Why some children are still on steroid beyond five years’ post-liver transplantation under tacrolimus
18th Annual Meeting of the American Society of Transplantation (AST), May 15-19, 1999. Chicago, IL, 1999. Ab stract: Transplantation 67(7):S231, 1999.
Incidence of post-transplant lymphoproliferative disorder in adults and children: Consecutive 1000 primary liver transplant recipients under tacrolimus
18th Annual Meeting of the American Society of Transplantation (AST), May 15-19, 1999. Chicago, IL, 1999. Abstract: Transplantation 67(7):S246, 1999.
Post-transplant lymphoproliferative disorder (PTLD) following adult liver transplantation: Retrospective study of over 4000 patients over 15 years from a single center
25th Annual Scientific Meeting, The American Society of Transplant Surgeons (ASTS), Chicago, IL, Transplantation 67(9);S587, 1999.
Hepatic artery complication following primary liver transplantation in adults and children: 1000 consecutive cases under tacrolimus
25th Annual Scientific Meeting, The American Society of Transplant Surgeons (ASTS), Chicago, IL, Transplantation 67(9);S599, 1999.
Reasons for long-term steroid use following primary adult liver transplantation under tacrolimus
25th Annual Scientific Meeting, The American Society of Transplant Surgeons (ASTS), Chicago, IL, Transplantation 67(9);S601, 1999.
J Reyes. Under tacrolimus, why some children are still on steroids beyond five-years post-liver transplantation
Fifth Congress of the International Liver Transplantation Society, Pittsburgh, PA, August 26-28, 1999. Abstract: Liver Transplantation and Surgery. 5(4); C-13, 12A, 1999.
Reasons for long-term steroid use following primary adult liver transplantation under tacrolimus
Fifth Congress of the International Liver Transplantation Society, Pittsburgh, PA, August 26-28, 1999. Abstract: Liver Transplantation and Surgery. 5(4); C-4, 12B, 1999.
Use of Mycophenolate Mofetil for tacrolimus-related chronic nephrotoxicity in liver transplant recipients
Fifth Congress of the International Liver Transplantation Society, Pittsburgh, PA, August 26-28, 1999. Abstract: Liver Transplantation and Surgery. 5(4); C-4, 13, 1999.
Post-transplant lymphoproliferative disorder in adults and children: Consecutive 1000 primary liver transplant recipients under tacrolimus
Fifth Congress of the International Liver Transplantation Society, Pittsburgh, PA, August 26-28, 1999. Abstract: Liver Transplantation and Surgery. 5(4); C-, 27A, 1999.
Incidence of post-transplant lymphoproliferative disorder (PTLD): Retrospective study of over 4000 adults after liver transplantation 15-years’ experience from a single center
Fifth Congress of the International Liver Transplantation Society, Pittsburgh, PA, August 26-28, 1999. Abstract: Liver Transplantation and Surgery. 5(4); C-8, 27B, 1999.
Prospective randomized trial of tacrolimus and steroids versus tacrolimus and Mycophenolate Mofetil in primary adult liver transplantation
Fifth Congress of the International Liver Transplantation Society, Pittsburgh, PA, August 26-28, 1999. Abstract: Liver Transplantation and Surgery. 5(4); C-25, 97, 1999.
Detection of early antigenemia (p-g65) in peripheral blood leukocytes and pre-emptive therapy for Cytomegalovirus infection in liver transplant recipients
Fifth Congress of the International Liver Transplantation Society, Pittsburgh, PA, August 26-28, 1999. Abstract: Liver Transplantation and Surgery. 5(4); C-35, 135, 1999.
Conversion of pediatric liver allograft recipients from Cyclosporin to tacrolimus for acute and chronic rejection: mean seven years’ follow up
Fifth Congress of the International Liver Transplantation Society, Pittsburgh, PA, August 26-28, 1999. Abstract: Liver Transplantation and Surgery. 5(4); C-38, 147, 1999.
Comparative study: Primary liver transplantation in children under tacrolimus and Cyclosporine
Fifth Congress of the International Liver Transplantation Society, Pittsburgh, PA, August 26-28, 1999. Abstract: Liver Transplantation and Surgery. 5(4); C-38, 148, 1999.
Impact of positive crossmatch due to IgG versus IgM antibodies in primary liver transplantation under tacrolimus in long term
Fifth Congress of the International Liver Transplantation Society, Pittsburgh, PA, August 26-28, 1999. Abstract: Liver Transplantation and Surgery. 5(4); C-26, 99, 1999.
Drug metabolism in older OLTx patients: Effects of donor and recipient age
Fifth Congress of the International Liver Transplantation Society, Pittsburgh, PA, August 26-28, 1999. Abstract: Liver Transplantation and Surgery. 5(4); C-27, 104, 1999.
Primary liver transplant under tacrolimus in infants, children, adults and seniors: 1000 consecutive cases: Mean follow up seven years’
Fifth Congress of the International Liver Transplantation Society, Pittsburgh, PA, August 26-28, 1999. Abstract: Liver Transplantation and Surgery. 5(4); C-27, 103, 1999.
End-stage renal failure amongst long-term survival of primary liver transplant recipients under tacrolimus: Adults and children
Fifth Congress of the International Liver Transplantation Society, Pittsburgh, PA, August 26-28, 1999. Abstract: Liver Transplantation and Surgery. 5(4); C-27, 105, 1999.
Conversion from tacrolimus toCyclosporine A following primary liver transplantation under tacrolimus
Fifth Congress of the International Liver Transplantation Society, Pittsburgh, PA, August 26-28, 1999. Abstract: Liver Transplantation and Surgery. 5(4); C-28, 106, 1999.
Assessment of renal function in liver and renal transplant patients
Fifth Congress of the International Liver Transplantation Society, Pittsburgh, PA, August 26-28, 1999. Abstract: Liver Transplantation and Surgery. 5(4); C-28, 107, 1999.
Time dependent changes in the kinetics of mycophenolate acid (MPA) in liver transplant patients
Fifth Congress of the International Liver Transplantation Society, Pittsburgh, PA, August 26-28, 1999. Abstract: Liver Transplantation and Surgery. 5(4); C-30, 114, 1999.
Mycophenolate Mofetil has no effect on tacrolimus pharmacokinetics in liver transplant patients
Fifth Congress of the International Liver Transplantation Society, Pittsburgh, PA, August 26-28, 1999. Abstract: Liver Transplantation and Surgery. 5(4); C-30, 116, 1999.
Outcome of hepatitis C viral (HCV) infection in primary adult liver transplant recipients compared to non-HCV under tacrolimus
Fifth Congress of the International Liver Transplantation Society, Pittsburgh, PA, August 26-28, 1999. Abstract: Liver Transplantation and Surgery. 5(4); C-33, 128, 1999.
Results of Interferon-Alpha for HCV infection post-liver transplantation: Results after actual five-to-seven years’ follow up
Fifth Congress of the International Liver Transplantation Society, Pittsburgh, PA, August 26-28, 1999. Abstract: Liver Transplantation and Surgery. 5(4); C-33, 129, 1999.
Comparative study of pharmacokinetic profile following intravenous infusion of tacrolimus in pediatric and adult liver transplant recipients
Fifth Congress of the International Liver Transplantation Society, Pittsburgh, PA, August 26-28, 1999. Abstract: Liver Transplantation and Surgery. 5(4); C-39, 150, 1999.
Rate of hepatic artery complication following primary liver transplantation in adults and children: 1000 consecutive cases under tacrolimus
Fifth Congress of the International Liver Transplantation Society, Pittsburgh, PA, August 26-28, 1999. Abstract: Liver Transplantation and Surgery. 5(4); C-42, 162, 1999.
Post-operative acute renal failure in liver transplant recipients under tacrolimus, Prednisone versus tacrolimus, Prednisone and Cellcept
Fifth Congress of the International Liver Transplantation Society, Pittsburgh, PA, August 26-28, 1999. Abstract: Liver Transplantation and Surgery. 5(4); C-42, 163, 1999.
Conversion from Cyclosporine to tacrolimus for chronic liver allograft rejection: More than six years’ actual follow up
Fifth Congress of the International Liver Transplantation Society, Pittsburgh, PA, August 26-28, 1999. Abstract: Liver Transplantation and Surgery. 5(4); C-49, 191, 1999.
Outcome of liver transplantation in alcoholic cirrhosis
Fifth Congress of the International Liver Transplantation Society, Pittsburgh, PA, August 26-28, 1999. Abstract: Liver Transplantation and Surgery. 5(4); C-51, 198, 1999.
Elevated serum alpha-feto protein among patients with end-stage liver disease and its clinical significance
Fifth Congress of the International Liver Transplantation Society, Pittsburgh, PA, August 26-28, 1999. Abstract: Liver Transplantation and Surgery. 5(4); C-57, 222, 1999.
Does plasma protein binding of mycophenolate acid affect its clearance
Fifth Congress of the International Liver Transplantation Society, Pittsburgh, PA, August 26-28, 1999. Abstract: Liver Transplantation and Surgery. 5(4); C-59, 231, 1999.
The pharmacokinetics of oral tacrolimus in liver transplant patients: Study of intra-individual variation
Fifth Congress of the International Liver Transplantation Society, Pittsburgh, PA, August 26-28, 1999. Abstract: Liver Transplantation and Surgery. 5(4); C-59, 232, 1999.
Assessment of renal function in liver transplant patients
AAPS Annual Meeting in San Francisco, CA, November 1998.
Evaluation of renal function in renal transplant patients on tacrolimus therapy. USP, May 1999
Pharmacokinetics of tacrolimus not altered by Mycophenolate Mofetil
International Therapeutic Drug Monitoring and Clinical Toxicology Meeting. Calne, Australia, September 1999.
Time dependent changes in the kinetics of mycophenolic acid in liver transplant patients
International Therapeutic Drug Monitoring and Clinical Toxicology Meeting, Calne, Austraila, September 1999.
Time dependent changes in the inetics of mycophenolic acid (MPA) in liver transplant patients
American College of Clinical Pharmacology, Annual Meeting, Washington, DC, 1999.
Time dependent changes in the kinetics of mycophenolic acid in liver transplant patients
Annual AAPS Meeting. New Orleans, LA, November 1999.
Evaluation of renal function in renal transplant patients on tacrolimus therapy
Annual AAPS Meeting. New Orleans, LA, November 1999.
Prospective randomized trial of tacrolimus and steroids versus tacrolimus, steroids and Mycophenolate Mofetil in primary adult liver transplantation
The Eighth Annual International Transplant Nurses Society Symposium and General Assembly. Toronto, Canada, September 9-11, 1999.
Reasons for long-term steroid use following primary adult liver transplantation under tacrolimus
The Eighth Annual International Transplant Nurses Society Symposium and General Assembly. Toronto, Canada, September 9-11, 1999.
Post-transplant lymphoproliferative disorder in adults and children: Consecutive 1000 primary liver transplant recipients
The Eighth Annual International Transplant Nurses Society Symposium and General Assembly. Toronto, Canada, September 9-11, 1999.
Why some children are still on steroids beyond five-years’ post liver transplantation? The Eighth Annual International Transplant Nurses Society Symposium and General Assembly. Toronto, Canada, September 9-11, 1999.
Conversion from Cyclosporine to tacrolimus for chronic liver allograft rejection: More than six years’ actual follow up
The Eighth Annual International Transplant Nurses Society Symposium and General Assembly. Toronto, Canada, September 9-11, 1999.
Impact of positive crossmatch due to IgG versus IgM antibodies in primary liver transplantation under tacrolimus in long term
The Eighth Annual International Transplant Nurses Society Symposium and General Assembly. Toronto, Canada, September 9-11, 1999.
Post-transplant lymphoproliferative disorder (PTLD) following adult liver transplantation: Retrospective study of over 4000 patients over 15 years’ from a single center
The Eighth Annual International Transplant Nurses Society Symposium and General Assembly. Toronto, Canada, September 9-11, 1999.
Liver transplantation for alcoholic-related liver disease under tacrolimus: Long-term results
The Eighth Annual International Transplant Nurses Society Symposium and General Assembly. Toronto, Canada, September 9-11, 1999.
Results of Interferon-Alpha for HCV infection post-liver transplantation: Results after actual five-to-seven years’ follow up
The Eighth Annual International Transplant Nurses Society Symposium and General Assembly. Toronto, Canada, September 9-11, 1999.
Use of Mycophenolate Mofetil for tacrolimus-related chronic nephrotoxicity in liver transplantation
The Eighth Annual International Transplant Nurses Society Symposium and General Assembly. Toronto, Canada, September 9-11, 1999.
The Eighth Annual International Transplant Nurses Society Symposium and General Assembly. Toronto, Canada, September 9-11, 1999.
Does tacrolimus offer virtual freedom from chronic rejection after primary liver transplantation (LTx)? Analysis of 6057 biopsies in 1055 LTx: Mean follow up after six years’
50th American Association for the Study of Liver Diseases, Dallas, TX, November 5-8, 1999. Abstract: Hepatology 30(4)2, 1999. Abstract #601.
Comparative study of post-transplant lymphoproliferative disorder and de novo cancer after liver transplantation
50th American Association for the Study of Liver Diseases, Dallas, TX, November 5-8, 1999. Abstract: Hepatology 30(4)2;173, 1999. Abstract #602.
Rate of post-transplant lymphoproliferative disorder (PTLD) under Cyclosporine and tacrolimus-based immunosuppression: Review of 4022 adult liver transplant patients
50th American Association for the Study of Liver Diseases, Dallas, TX, November 5-8, 1999. Abstract: Hepatology 30(4)2, 1999. Abstract #602.
Under tacrolimus’ outcome of hepatitis viral (HCV) infection in primary adult liver transplant recipients compared to non-HCV: Mean follow up of 93 months
50th American Association for the Study of Liver Diseases, Dallas, TX, November 5-8, 1999. Abstract: Hepatology 30(4)2; 179A, 1999. Abstract #74.
Does tacrolimus offer virtual freedom from chronic rejection after primary liver transplantation (LTx)?: Analysis of 5252 biopsies in 1055 LTx: Mean follow up six years
Fourth International Conference on New Trends in Clinical and Experimental Immunosuppression, Geneva, Switzerland, 1999.
Development of quantitative pcr for BK virus detection in urine and its role in management of allograft viral infection masquerading as acute rejection
First Joint Annual Meeting of the American Society of Transplant Surgeons and the American Society of Transplantation, Chicago, IL, May 13-20, 2000. Abstract: Transplantation 69(8)S136, 2000. Abstract #96.
Outcome after steroid withdrawal in adult renal transplant patients receiving tacrolimus-based immunosuppression
First Joint Annual Meeting of the American Society of Transplant Surgeons and the American Society of Transplantation, Chicago, IL, May 13-20, 2000. Chicago, IL, May 13-20. Abstract: Transplantation 69(8)S224, 2000. Abstract #425.
Rate of post-transplant lymphoproliferative disorders (PTLD) in children under Cyclosporine and tacrolimus: 766 Consecutive Recipients: 15 years’ experience
First Joint Annual Meeting of the American Society of Transplant Surgeons and the American Society of Transplantation, Chicago, IL, May 13-20, 2000. Abstract: Transplantation 69(8)317, 2000. Abstract #787.
Causes of re-transplantation, rate and survival after 4000 consecutive primary liver transplantations from a single center with 15 years’ median follow up
First Joint Annual Meeting of the American Society of Transplant Surgeons and the American Society of Transplantation, Chicago, IL, May 13-20, 2000. Abstract: Transplantation 69(8)S320, 2000.
An analysis of early renal transplantation protocol biopsies—the high incidence of subclinical acute rejection. Transplant 2000, Chicago, IL, May 13-20
First Joint Annual Meeting of the American Society of Transplant Surgeons and the American Society of Transplantation, Abstract: Transplantation 69(8)S365, 2000.
Survival patterns after live transplantation: Effect of age, gender, and era in 4000 consecutive patients from a single center with 15-year median follow up
American Surgical Association 120th Annual Meeting. Philadelphia , PA, April 6-8, 2000.
Bile duct complications following liver transplantation in adults and children: 1000 consecutive patients
International Liver Transplantation Society Sixth Congress. Buenos Aires, Argentina, June 23-23, 2000. Abstract: Liver Transplantation 6(3), 2000. Abstract #57.
Outcome of liver transplantation for hemophiliacs and HCV, with or without HBV and HIV infection under tacrolimus: Nine years’ experience from a single center
International Liver Transplantation Society Sixth Congress. Buenos Aires , Argentina, June 23-23, 2000. Abstract: Liver Transplantation 6(3), 2000. Abstract #94.
Tacrolimus offers virtual freedom from chronic rejection after primary liver transplantation (LTx): Review of 5252 biopsies in 1055 LTx mean follow up—Six years
International Liver Transplantation Society Sixth Congress. Buenos Aires, Argentina, June 23-23, 2000. Abstract: Liver Transplantation 6(3), 2000. Abstract #105.
Causes of death after liver transplantation (LTx) in 4000 consecutive patients: Median follow up—15-years
International Liver Transplantation Society Sixth Congress. Buenos Aires, Argentina, June 23-23, 2000. Abstract: Liver Transplantation 6(3), 2000. Abstract #110.
Causes of re-transplantation after 4000 consecutive primary liver transplantations from a single center with 15-years’ median follow-up rate and survival
International Liver Transplantation Society Sixth Congress. Buenos Aires, Argentina, June 23-23, 2000. Abstract: Liver Transplantation 6(3), 2000. Abstract #112.
Incidence of de novo cancer and post-transplant lymphoproliferative disorder (PTLD) after liver transplantation under tacrolimus: Comparative study
International Liver Transplantation Society Sixth Congress. Buenos Aires, Argentina, June 23-23, 2000. Abstract: Liver Transplantation 6(3), 2000. Abstract #129.
Under Cyclosporine and tacrolimus’ rate of post-transplant lymphoproliferative disorders (PTLD) in children: 766 consecutive recipients 15-years’ experience
International Liver Transplantation Society Sixth Congress. Buenos Aires, Argentina, June 23-23, 2000. Abstract: Liver Transplantation 6(3), 2000. Abstract #131.
Pediatric liver transplantation in 808 consecutive children: 18-years’ experience from a single center
First Congress of the International Pediatric Transplant Association. Venice, Italy, August 23-25, 2000.
Comparison of post-transplant lymphoproliferative disorders (PTLD) in children under Cyclosporine and tacrolimus: 766 consecutive recipients: 15-years’ experience
First Congress of the International Pediatric Transplant Association. Venice, Italy, August 23-25, 2000.
Rate and causes of re-transplantation with survival after 4000 primary liver transplantations from a single center: Two-to-19 years’ follow up
XVII International Congress of the Transplantation Society. Rome, Italy, August 27 – September 1, 2000.
Causes of death after liver transplantation (LTx) in 4000 consecutive patients: Follow up two-to-19 years’
XVII International Congress of the Transplantation Society. Rome, Italy, August 27 – September 1, 2000.AB Jain, R Kashyap, SF Dodson, D Kramer, JJ Fung. Prospective randomized trial of tacrolimus and steroids versus tacrolimus, steroids and mycophenolate mofetil in primary liver transplant: A complete report. XVII International Congress of the Transplantation Society. Rome, Italy, August 27 – September 1, 2000.
Incidence of de novo cancer and post-transplant lymphoproliferative disorder (PTLD) after liver transplantation under tacrolimus: Comparative study
Ninth ITNS Symposium and General Assembly. Las Vegas, NE, September 7-10, 2000.
Experience of liver transplantation in patients with human immunodeficiency virus—type I (HIV)
Ninth ITNS Symposium and General Assembly. Las Vegas, NE, September 7-10, 2000.
Under Cyclosporine and tacrolimus’ rate of post-transplant lymphoproliferative disorders (PTLD) in children: 766 Consecutive recipients: 15-years’ experience
Ninth ITNS Symposium and General Assembly. Las Vegas, NE, September 7-10, 2000.
Prospective randomized trial of tacrolimus and steroids versus tacrolimus, steroids and Mycophenolate Mofetil in primary liver transplantation: A complete report
Ninth ITNS Symposium and General Assembly. Las Vegas, NE, September 7-10, 2000.
Survival patterns after liver transplantation: Effect of age, gender, and era in 4000 consecutive patients from a single center with two-to-18 years’ follow up
Ninth ITNS Symposium and General Assembly. Las Vegas, NE, September 7-10, 2000.
Causes of re-transplantation after 4000 consecutive primary liver transplantations from a single center with two-to-18 years’ follow up
Ninth ITNS Symposium and General Assembly. Las Vegas, NE, September 7-10, 2000.
Does tacrolimus offer virtual freedom from chronic rejection after primary liver transplantation (LTx)? Analysis of 5252 biopsies in 1048 LTx—Mean follow up: Six years
Ninth ITNS Symposium and General Assembly. Las Vegas, NE, September 7-10, 2000.
Question of steroid withdrawal under tacrolimus for primary biliary cirrhosis (PBC), primary sclerosing cholangitis (PSC) and autoimmune hepatitis (AIH) after liver transplantation and long-term survival
Transplant 2001–The Second Joint American Transplant Meeting, Chicago, IL, May 12-16, 2001.
Use of Rapamycin in pancreatic transplantation under tacrolimus-based immunosuppression
Transplant 2001–The Second Joint American Transplant Meeting, Chicago, IL, May 12-16, 2001.
Need for ribavirin dose adjustment in relation to renal function for treatment of recurrent HCV infection in post liver transplantation
Transplant 2001–The Second Joint American Transplant Meeting, Chicago, IL, May 12-16, 2001.
Role of Mycophenolate Mofetil (MMF) in liver transplantation (LTx) for HCV-related end-stage liver failure (a prospective randomized trial)
Transplant 2001–The Second Joint American Transplant Meeting, Chicago, IL, May 12-16, 2001.
Comparison of post-transplant lymphoproliferative disorders (PTLD) in children under Cyclosporine and tacrolimus: 766 consecutive recipients: 15-years’ experience
Transplant 2001–The Second Joint American Transplant Meeting, Chicago, IL, May 12-16, 2001.
Pediatric liver transplantation in 808 consecutive children: 18-years’ experience from a single center
Transplant 2001–The Second Joint American Transplant Meeting, Chicago, IL, May 12-16, 2001.
Pediatric liver transplantation in 808 consecutive children: 18-years’ experience from a single center. Accepted as poster presentation at the Festschthrift Honoring Thomas E. Starzl, M.D., Ph.D. Pittsburgh, PA, April 27-28, 2001
Tacrolimus offers virtual freedom from chronic rejection after primary liver transplantation (LTx) in children and adults in long-term follow up. Accepted as poster presentation at the Festschthrift Honoring Thomas E. Starzl, M.D., Ph.D. Pittsburgh, PA, April 27-28, 2001
Prospective randomized trial of tacrolimus and steroids versus tacrolimus, steroids and Mycophenolate Mofetil in primary liver transplantation. Accepted as poster presentation at the Festschthrift Honoring Thomas E. Starzl, M.D., Ph.D. Pittsburgh, PA, April 27-28, 2001
Absence of chronic rejection under tacrolimus in pediatric liver transplant recipients: Mean follow up of nine years
Accepted as poster at the Seventh International Liver Transplantation Society Meeting ELTA, Berlin, Germany, July 11-13, 2001. Liver Transplantation 7(6)C-47; 2001. Abstract #185.
Pediatric Liver Transplantation in 808 consecutive children: 18-years’ experience from a single center. Accepted as poster at the Seventh International Liver Transplantation Society Meeting ELTA, Berlin, Germany, July 11-13, 2001. Liver Transplantation 7(6)C-78; 2001. Abstract #312.
Use of Mycophenolate Mofetil (MMF) for chronic rejection in liver allograft under tacrolimus. Accepted as oral presentation
Seventh International Liver Transplantation Society Meeting ELTA, Berlin, Germany, July 11-13, 2001. Liver Transplantation 7(6)C-83; 2001. Abstract #330.
Incidence and outcome of cytomegaloviral (CMV) hepatitis in adult post-liver transplant allograft under tacrolimus. Accepted as oral presentation
Seventh International Liver Transplantation Society Meeting ELTA, Berlin, Germany, July 11-13, 2001. Liver Transplantation 7(6)C-14; 2001. Abstract #54.
The question of steroid withdrawal under tacrolimus for primary biliary cirrhosis (PBC), primary sclerosing cholangitis (PSC) and autoimmune hepatitis (AIH) after liver transplantation and long-term survival. Accepted as a poster presentation
Seventh International Liver Transplantation Society Meeting ELTA, Berlin, Germany, July 11-13, 2001. Liver Transplantation 7(6)C-51; 2001. Abstract #228.
Need for ribavirin-dose adjustment in relation to renal function for treatment of recurrent HCV infection in post-liver transplant patients. Accepted as a poster presentation
Seventh International Liver Transplantation Society Meeting ELTA, Berlin, Germany, July 11-13, 2001. Liver Transplantation 7(6)C-5; 2001. Abstract #19.
Need for ribavirin-dose adjustment in relation to renal function for treatment of recurrent HCV infection in post-liver transplant patients. Accepted as a poster presentation
Seventh International Liver Transplantation Society Meeting ELTA, Berlin, Germany, July 11-13, 2001. Liver Transplantation 7(6)C-33; 2001. Abstract #130.
Need for ribavirin-dose adjustment in relation to renal function for treatment of recurrent HCV infection in post-liver transplant patients. Accepted as a poster presentation. Accepted as a poster presentation
Hepatitis Single Topic Conference: New Therapeutic Strategies for Hepatitis C. Chicago, IL, June 15-16, 2001.
Rate of post transplant lymphoproliferative disorder under Cyclosporine (CsA) and tacrolimus (TAC) after liver transplantation (LTx) in adults and children
The 3rd Congress of the International Transplant Coordinators Society, Nagoya, Japan, July 22-27, 2001.
Survival patterns post liver transplantation: Effect of age, general and era in consecutive 4000 patients with median 15 years’ follow up from single center
The 3rd Congress of the International Transplant Coordinators Society, Nagoya, Japan, July 22-27, 2001.
Gadomski, K Nestler, L Kingery, S Rohal, C Hartner, A Rafail, E Kallenborn, K Newell. Longitudinal follow up after liver transplantation with hepatic C viral infection
The 3rd Congress of the International Transplant Coordinators Society, Nagoya, Japan, July 22-27, 2001.
Prospective randomized trial of tacrolimus and steroid vs. tacrolimus, steroid and Mycophenolate Mofetil in primary liver transplantation
The 3rd Congress of the International Transplant Coordnators Society, Nagoya, Japan, July 22-27, 2001.
Kallenborn, K Newell. Surgical/Nonsurgical, immunological/nonimmunological, early and late complications after primary liver transplantation: An analysis of 1000 consecutive patients with 8-11 years’ follow up
The 3rd Congress of the International Transplant Coordinators Society, Nagoya, Japan, July 22-27, 2001.
Tacrolimus offers virtual freedom from chronic rejection after primary liver transplantation (LTx) in children and adults in long-term follow up
The 3rd Congress of the International Transplant Coordinators Society, Nagoya, Japan, July 22-27, 2001.
Incidence and outcome of cytomegaloviral (CMV) hepatitis in adult post liver transplant allograft under tacrolimus
The 3rd Congress of the International Transplant Coordinators Society, Nagoya, Japan, July 22-27, 2001.
Question of steroid withdrawal under tacrolimus for primary biliary cirrhosis (PBC) primary sclerosing cholangitis (PSC) and autoimmune hepatitis (AIH) after liver transplantation and long-term survival
The 3rd Congress of the International Transplant Coordinators Society, Nagoya, Japan, July 22-27, 2001.
Stock, AB Jain, L Boig, C. Shay, M. Gadomsky, K. Nestler, L. Kingery, S. Rohal, M. Funovits, C. Hartner, B. Yelochan, A. Rafail, N. Marino, E. Kallenborn, K. Newell. Longitudinal follow up after liver transplantation with hepatic C viral infection
International Transplant Nurses Society, ITNS 10th Anniversary Symposium, Churchill College, Cambridge, England, August 29-September 1, 2001.
Total absence of chronic rejection under tacrolimus in pediatric liver transplant recipient: Mean follow up of nine years
International Transplant Nurses Society, ITNS 10th Anniversary Symposium, Churchill College, Cambridge, England, August 29-September 1, 2001.
Role of Mycophenolate Mofetil (MMF) in Liver Transplantation (LTx) for HCV-related end-stage liver failure (a prospective, randomized trial). International Transplant Nurses Society, ITNS 10th Anniversary Symposium, Churchill College, Cambridge, England, August 29-September 1, 2001.
Use of Rituximab (Chimeric Anti CD20 Antibody) in post transplant lymphoproliferative disorder after liver, kidney, and pancreas transplantation
International Transplant Nurses Society, ITNS 10th Anniversary Symposium, Churchill College, Cambridge, England, August 29-September 1, 2001.
Flynn, ST Grogan, K Emmett, N Harpur, JJ Fung. Incidence and outcome of cytomegaloviral (CMV) hepatitis in adult post liver transplant allograft under tacrolimus
International Transplant Nurses Society, ITNS 10th Anniversary Symposium, Churchill College, Cambridge, England, August 29-September 1, 2001.
Need for Ribovirin dose adjustment in relation to renal function for treatment of recurrent HCV infection in post liver transplant patients
International Transplant Nurses Society, ITNS 10th Anniversary Symposium, Churchill College, Cambridge, England, August 29-September 1, 2001.
Prospective randomized trial of tacrolimus and steroids versus tacrolimus, steroids and Mycophenolate Mofetil in primary liver transplantation. Accepted as a poster presentation
Tenth ESOT Congress 2001. Lisbon, Portugal, October 6-11, 2001.
Longitudinal follow up after liver transplantation (LTx) with hepatitis C viral infection. Accepted as an oral presentation
Tenth ESOT Congress 2001. Lisbon, Portugal, October 6-11, 2001.
Tacrolimus offers virtual freedom from chronic rejection after primary liver transplantation (LTx) in children and adults in long-term follow up. Accepted as an oral presentation
Tenth ESOT Congress 2001. Lisbon, Portugal, October 6-11, 2001.
Profound interaction between tacrolimus and protease inhibitor drugs in liver transplant patients (LTx). Accepted as an oral presentation
Tenth ESOT Congress 2001. Lisbon, Portugal, October 6-11, 2001.
Rate of post-transplant lymphoproliferative disorder under Cyclosporin (CsA) and tacrolimus (TAC) after liver transplantation (LTx) in adults and children. Accepted as a poster presentation
Tenth ESOT Congress 2001. Lisbon, Portugal, October 6-11, 2001.
Use of Rituximab (Chimeric anti-CD20 antibody) in post-transplant lymphoproliferative disorder (PTLD) after liver, kidney and pancreas transplantation. Accepted as poster presentation
Tenth ESOT Congress 2001. Lisbon, Portugal, October 6-11, 2001
B. Jain, G. Mazariegos, Randeep S. Kashyap, John J. Fung, Thomas E. Starzl, Jorge Reyes. Tacrolimus offers total absence of chronic rejection in pediatric liver transplant recipient: Follow up of 7-10 years
The Liver Meeting 2001, The American Association for the Study of Liver Diseases 52nd Annual Meeting, Dallas, Texas, November 9-13, 2001. Hepatology 34(4):2, 2001, p. 246A. Abstract #292.
B. Jain, Randeep S. Kashyap, K. Abu-Elmagd, P. A. Fontes, J.J. Fung, M. Nalesnik. Use of Rituximab (chimeric anti CD20 antibody) in post transplant lymphoproliferative disorder (PTLD) after liver transplantation
The Liver Meeting 2001, The American Association for the Study of Liver Diseases 52nd Annual Meeting, Dallas, Texas, November 9-13, 2001. Hepatology 34(4):2, p. 285A, 2001. Abstract #452.
S. Kashyap, A.B. Jain, J.J. Fung. Impact of cytomegaloviral (CMV) hepatitis in adult post liver transplant allograft under tacrolimus
The Liver Meeting 2001, The American Association for the Study of Liver Diseases 52nd Annual Meeting, Dallas, Texas, November 9-13, 2001. Hepatology 34(4):2, p. 285A, 2001. Abstract #453.
S. Kashyap, B. Eghtesad, S. Obaid, V. Ramesh, K. Akhtar, J.J. Fung. Ribavirin Dose Adjustment in relation to renal function is mandatory for treatment of recurrent HCV infection in post liver transplant patients
The Liver Meeting 2001, The American Association for the Study of Liver Diseases 52nd Annual Meeting, Dallas, Texas, November 9-13, 2001. Hepatology 34(4):2 p. 409A, 2001. Abstract #947.
Pediatric Liver Transplantation in 808 Consecutive children: 20 Years’ Experience from a Single Center. The 2nd International Congress on Immunosuppression, San Diego, CA, December 6-8, 2001.
Use of Rituximab (Chimeric Anti-CD20 Antibody) in Post-Transplant Lymphoproliferative Disorder (PTLD) After Liver Transplantation (LTx). The 2nd International Congress on Immunosuppression, San Diego, CA, December 6-8, 2001.
Role of Mycophenolate Mofetil (MMF) in Liver Transplantation (LTx) for HCV-Related End-Stage Liver Failure (A Prospective Randomised Trial. The 2nd International Congress on Immunosuppression, San Diego, CA, December 6-8, 2001.
A Pilot Trial of Tacrolimus and Sirolimus in Renal Transplantation. The 2nd International Congress on Immunosuppression, San Diego, CA, December 6-8, 2001.
Use of Mycophenolate Mofetil (MMF) for Chronic Rejection in Liver Allograft Under Tacrolimus
The 2nd International Congress on Immunosuppression, San Diego, CA, December 6-8, 2001.AB Jain, G. Mazariegos, RS Kashyap, JJ Fung, TE Starzl, J Reyes. Absence of Chronic Rejection Under Tacrolimus in Pediatric Liver Transplant Recipients: Mean Follow Up of Nine Years. The 2nd International Congress on Immunosuppression, San Diego, CA, December 6-8, 2001.
Question of Steroid Withdrawal Under Tacrolimus for Primary Biliary Cirrhosis (PBC), Primary Sclerosing Cholangitis (PSC) and Autoimmune Hepatitis (AIH) After Liver Transplantation and Long-Term Survival. The 2nd International Congress on Immunosuppression, San Diego, CA, December 6-8, 2001.
Profound Interaction Between Tacrolimus Anti-HIV Drugs in Liver Transplant Patients (LTx)
The 2nd International Congress on Immunosuppression, San Diego, CA, December 6-8, 2001.
Pokharna, Jorge D. Reyes, M Nalesnik, TV Cacciarelli, JJ Fung, TE Starzl. Incidence of Post-Transplant Lymphoproliferative Disorder (PTLD) Among Liver Transplant Recipients in Adults and Children Under Cyclosporine and Tacrolimus Therapy: 20-Years’ Experience from a Single Center
122nd Annual Meeting of the American Surgical Association, The Homestead, Hot Springs, VA, April 25-27, 2002.
Liver Transplantation in Patients Co-Infected with HIV and Hepatitis C. American Transplant Congress, Transplant 2002, Washington, DC, April 26-May 1, 2002. Am J Transpl 2;(Suppl 3):139, Abstract #5.
Prevention of Recurrent Hepatitis B Virus after Liver Transplantation with Restricted Elimination of Hepatitis B Immune Globulin. American Transplant Congress, Transplant 2002, Washington, DC, April 26-May 1, 2002. Am J Transpl 2;(Suppl 3):140, Abstract #11.
Venkataramanan, R Shapiro, VP Scantlebury, S Potdar, CA Bonham, M Ragni, JJ Fung. The Interaction between Anti-Retroviral Agents and Tacrolimus in Liver and Kidney Transplant Patients
American Transplant Congress, Transplant 2002, Washington, DC, April 26-May 1, 2002. Am J Transpl 2:(Suppl 3):234, Abstract #385.
Causes of Mortality Beyond One Year Following Pediatric Liver Transplant Under Tacrolimus
American Transplant Congress, Transplant 2002, Washington, DC, April 26-May 1, 2002. Am J Transpl 2(Suppl 3):295, Abstract #625.
Tacrolimus Offers Almost Total Absence of Chronic Rejection in Pediatric Liver Transplant Recipients: Follow Up of 7-10 Years
American Transplant Congress, Transplant 2002, Washington, DC, April 26-May 1, 2002. Am J Transpl 2:(Suppl 3):352, Abstract #853.
The Impact of EBV-Negative Post-Transplant Lymphoproliferative Disorder on Survival in Adult and Pediatric Solid Organ Transplant Recipients
American Transplant Congress, Transplant 2002, Washington, DC, April 26-May 1, 2002. Am J Transpl 2;(Suppl 3):427, Abstract #1147.
Venkataramanan, B Eghtesad, R Shapiro, VP Scantlebury, S Potdar, CA Bonham, M Ragni, JJ Fung. The Interaction Between Anti-Retroviral Agents and Tacrolimus in Liver and Kidney Transplant in HIV+ Patients
The Eighth Annual Congress of the International Liver Transplantation Society, Chicago, IL, June 13-15, 2002. Liver Transplantation 8(6):C-6, Abstract #24.
Effect of T-Tube Clamping on Absorption of Rapamycin in Liver Transplantation Recipients. The Eighth Annual Congress of the International Liver Transplantation Society, Chicago, IL, June 13-15, 2002. Liver Transplantation 8(6):C-6, Abstract #25.
Venkataramanan, JA Fridell, B Eghtesad, MV Ragni, JJ Fung. Nelfinavir, A Protease Inhibitor, Increases Sirolimus Levels in Liver Transplant Patients: A Case Report
The Eighth Annual Congress of the International Liver Transplantation Society, Chicago, IL, June 13-15, 2002. Liver Transplantation 8(6):C-10, Abstract #37.
Utilization of Livers from Non-Heartbeating Donors (NHBD): A Single Center Experience
The Eighth Annual Congress of the International Liver Transplantation Society, Chicago, IL, June 13-15, 2002. Liver Transplantation 8(6): C17, Abstract #66.
Prevention of Recurrent Hepatitis B Virus After Liver Transplantation with Restricted Elimination of Hepatitis B Immune Globulin. The Eighth Annual Congress of the International Liver Transplantation Society, Chicago, IL, June 13-15, 2002. Liver Transplantation 8(6): C-35, Abstract #138.
Use of Rituximab (Chimeric Anti-CD20 Antibody) in Post-Transplant Lymphoproliverative Disorder (PTLD) After Liver Transplantation. The Eighth Annual Congress of the International Liver Transplantation Society, Chicago, IL, June 13-15, 2002. Liver Transplantation 8(6):C-42, Abstract #168.
Mortality Beyond One Year following Liver Transplant Under Tacrolimus Immunosuppression in Pediatric Patients
The Eighth Annual Congress of the International Liver Transplantation Society, Chicago, IL, June 13-15, 2002. Liver Transplantation 8(6):C-68, Abstract #272.
Pancreas and kidney-pancreas transplantation under a tolerogenic regimen of preconditioning with thymoglobulin and post-transplant tacrolimus
XIX International Congress of The Transplantation Society, Miami, FL, August 25-30, 2002. Transplantation 74(4):Suppl, Abstract #85.
Profound interaction between tacrolimus, rapamycin and anti-HIV drugs in liver and kidney transplant patients
XIX International Congress of The Transplantation Society, Miami, FL, August 25-30, 2002. Transplantation 74(4):Suppl, Abstract #172.
Causes of late mortality beyond one year following pediatric liver transplant under tacrolimus
XIX International Congress of The Transplantation Society, Miami, FL, August 25-30, 2002. Transplantation 74(4):Suppl, Abstract #392.
Simultaneous heart-liver transplantation: A worthwhile effort? XIX International Congress of The Transplantation Society, Miami, FL, August 25-30, 2002. Transplantation 74(4):Suppl, Abstract #622.
Utilization of livers from non-heartbeating donors (NHBD): A single center experience
XIX International Congress of The Transplantation Society, Miami, FL, August 25-30, 2002. Transplantation 74(4):Suppl, Abstract #1664.
Pregnancy post liver, kidney and kidney + pancreas transplant under tacrolimus
XIX International Congress of The Transplantation Society, Miami, FL, August 25-30, 2002. Transplantation 74(4):Suppl, Abstract #2106.
Pregnancy After Liver Transplantation Under Tacrolimus: A Single Center’s Experience Update at 13 Years. Presented at the XIX International Congress of The Transplantation Society, Miami, Florida, August 25-30, 2002. (GET ABSTRACT INFO)
De novo malignancy among intestinal allograft recipients
XIX International Congress of The Transplantation Society, Miami, FL, August 25-30, 2002. Transplantation 74(4):Suppl, Abstract #2710.
Safety and efficacy of low-dose thymoglobulin (rabbit anti-thymocyte globulin) for steroid-resistant rejection after pancreas transplantation under tacrolimus
XIX International Congress of The Transplantation Society, Miami, FL, August 25-30, 2002. Transplantation 74(4):Suppl, Abstract #2876.
The use of preconditioning and postoperative monotherapy in African-American kidney and other organ recipients. XIX International Congress of The Transplantation Society, Miami, FL, August 25-30, 2002. Transplantation 74(4):Suppl, Abstract #3334.
Efficacy of low dose thymoglobulin versus OKT3 in steroid-resistant rejections (SRR) after kidney transplantation under tacrolimus
XIX International Congress of The Transplantation Society, Miami, FL, August 25-30, 2002. Transplantation 74(4):Suppl, Abstract #3340.
Kidney transplantation under tolerogenic regimen of thymoglobulin preconditioning and post-transplant tacrolimus monotherapy
XIX International Congress of The Transplantation Society, Miami, FL, August 25-30, 2002. Transplantation 74(4):Suppl, Abstract #3343.
Incidence of post-transplant lymphoproliferative disorder (PTLD) among liver transplant recipients in adults and children under cyclosporine and tacrolimus therapy: 20 year experience from a single center
The Art of Transplant Nursing 11th Annual Symposium and General Assembly, Westin Convention Center Hotel, Pittsburgh, PA, September 18-21, 2002.
Primary oxalosis: A decade of experience after liver and kidney transplantation from a single center
The Art of Transplant Nursing 11th Annual Symposium and General Assembly, Westin Convention Center Hotel, Pittsburgh, PA, September 18-21, 2002.
Brautigam S, Flohr J. Use of Rapamycin in pancreatic transplantation under tacrolimus-based immunosuppression
The Art of Transplant Nursing 11th Annual Symposium and General Assembly, Westin Convention Center Hotel, Pittsburgh, PA, September 18-21, 2002.
More than ten years’ actual follow up: Conversion from Cyclosporine (CyA) to tacrolimus for chronic liver allograft rejection
The Art of Transplant Nursing 11th Annual Symposium and General Assembly, Westin Convention Center Hotel, Pittsburgh, PA, September 18-21, 2002.
Use of low-dose tacrolimus, Rapamycin and steroids for primary combined kidney and pancreas transplantation
The Art of Transplant Nursing 11th Annual Symposium and General Assembly, Westin Convention Center Hotel, Pittsburgh, PA, September 18-21, 2002.
Surgical/nonsurgical, immunological/nonimmunological, early and late complications after primary liver transplantation. An analysis of 1,000 consecutive patients with 8-11 years’ follow up
The Art of Transplant Nursing 11th Annual Symposium and General Assembly, Westin Convention Center Hotel, Pittsburgh, PA, September 18-21, 2002.
Profound interaction between tacrolimus, rapamycin and anti-HIV drugs in liver and kidney transplant patients
The Art of Transplant Nursing 11th Annual Symposium and General Assembly, Westin Convention Center Hotel, Pittsburgh, PA, September 18-21, 2002.
Hepatocellular carcinoma: Advances in diagnosis and treatment
Hepatocellular Carcinoma Symposium, Istituto Mediterraneo per i Trapianti e Terapie ad Alta Specializzazione (ISMETT), Palermo, Italy, October 5, 2002.
Immunosuppression in liver Transplantation and role of mycophenolate Mofetil: Liver Transplantation conference, Nagasaki Japan, April 10, 2003.
Rafail, John J. Fung
Effect of Coadministered Lopinavir and Ritonavir (Kaletra) on Tacrolimus Blood Concentration in Liver Transplantation Patients. Liver Transplantation, Vol 9, No 9 (September), 2003:pp 954-960.
Impact of hepatitis C viral (HCV) infection in primary cadaveric liver allograft v/s primarily living liver allograft in 100 consecutive liver transplant patients
54th Annual Meeting of the American Association for the Study of Liver Diseases, Boston, October 24-28, 2003. Abstract#770, Suppl 1, Hepatology. 34(4);pp.532A
Comparison of Early Graft Function and Complications of Pancreas Transplant Recipients in Histidine-Tryptophan-ketoglutarate-HTK Solution
9th Congress of the International Pancreas and Islet Transplant Association, July 8th- 11th, 2003, Dublin Ireland, August 27, 2003. Abstract#30 Transplantation 76(4); p. S-28, July 2003.
Percutaneous Ultrasound Guided Pancreas Allograft Biopsy Single Center Experience
Dublin Ireland, 9th Congress of the International Pancreas and Islet Transplant Association, July 8th- 11th, 2003. Abstract#035 Transplantation 76(4); p. S-29, August 27, 2003.
Successful Reversal of Refractory Acute Rejection with Campath 1H in Pancreas Transplantation Recipients, 9th Congress of the International Pancreas and Islet Transplant Association, Dublin Ireland , July 8th- 11th, 2003. Abstract#038 Transplantation 76(4); p.S-30, August 27, 2003.
Abstract#0110 Transplantation 76(4); p. S-54, August 27, 2003.
Lymphoproliferative Disorder (PTLD) In Children and Adults under Tacrolimus: 2, 000 consecutive Liver Transplant Patients: 12 Years Experience. Post-Transplant
9th Meeting of International Liver Transplant. May 30 – June 4, 2003, Barcelona Spain. Liver Transplantation. June 2003, Vol 9 No 6. Abstract#88, pp. C-22.
Use of mycophenolate mofetil (MMF) for tacrolimus-related, chronic nephrotoxicity in post liver transplant (LTX) patients: long-term prospective trial with minimum six years follow up
9th Meeting of International Liver Transplant. May 30 – June 4, 2003, Barcelona Spain. Liver Transplantation. June 2003 Vol 9 No 6. Abstract#169, pp. C-43.
Profound drug interaction with a combination of two protease inhibitors (PI: ritonavir and lopinavir: kaletra) and tacrolimus in post-liver transplant (LTX) patients with HIV infection
9th Meeting of International Liver Transplant. May 30 – June 4, 2003, Barcelona Spain. Pittsburgh, PA, USA. Liver Transplantation. June 2003 Vol 9 No 6. Abstract# 323, pp. C-81.
American Transplant Congress, May 30-June 4, 2003, Washington DC, Abstract#397 American Journal of Transplantation. Suppl, 5 (3); pp. 253.
American Transplant Congress, May 30-June, 2003, Washington DC, Abstract#670, American Journal of Transplantation. Suppl, 5. (3); pp. 324.
Infectious complications in recipients of liver transplantation co-infected with human immunodeficiency virus (HIV)American. American Transplant Congress, May 30-June, 2003, Washington DC, Abstract#1100, American Journal of Transplantation. Suppl.5. (3);pp. 433.
Surgery, Comparison of histidine- tryptophanketoglutarate (HTK) solution versus university of Wisconsin (UW) solution for organ preservation in liver transplantation
American Transplant Congress, May 30-June, 2003, Washington DC, Abstract#1172, American Journal of Transplantation. Suppl. 5. (3);pp. 452.
Use of Lamivudine Prophylaxis with short course of hyperimmune hepatitis B Immunoglobulin (HBIG) for hepatitis B core antibody (HbcAB) positive liver allograft recipients who are hepatitis B surface antibody (HbsAB) and hepatitis B surface antigen (HbsAg) negative
Accepted as poster presentation at the 12th AASLD Hepatitis single topic conference, Chicago March 12- 13 2004.
Does valgan (Ganciclovir hydrochloride) provide effective prophylaxis against cytomegaloviral (CMV) infection in liver transplant recipients? Accepted as poster presentation at the EASL 2004 39th Annual Meeting Berlin Germany, April 14-18, 2004.
Cadaveric liver allograft versus living donor allograft for hepatitis C viral infection in 100 consecutive liver transplant recipients under tacrolimus: Single Center Experience
Accepted as oral presentation at the EASL 2004 39th Annual Meeting Berlin Germany, April 14-18, 2004.
Use of mycophenolate mofetil (MMF) for tacrolimus-related, chronic nephrotoxicity in post liver transplantation (LTX) patients: Long-Term prospective trial with minimum six years’ follow up
Accepted as oral presentation at the 13th Annual ITNS Symposium and General Assembly. October 14-16, 2004 Vancouver, BC Canada.
Effect of coadministered lopinavir and ritonavir (KALETRA®) on tacrolimus blood concentration in liver transplant patients
Accepted as oral presentation at the 13th Annual ITNS Symposium and General Assembly October 14-16, 2004 Vancouver, BC Canada.
Value of ribavirin concentration measurement in plasma/blood in post liver transplant patients with hepatitis C virus (HCV) Infection
Accepted as oral presentation at the 13th Annual ITNS Symposium and General Assembly. October 14-16, 2004 Vancouver, BC Canada.
De Novo Breast Cancer in patients with liver transpantation: University of Pittsburgh experience and review of the literature
Accepted as oral presentation at the 13th Annual ITNS Symposium and General Assembly October 14-16, 2004 Vancouver, BC Canada.
Safety and efficacy profile of pegylated interferon 2 B (PEGINTRON) V/S pegylated interferon 2A (PEGASYS) in post liver transplant (LTx) hepatitis C virus (HCV) genotype1A/1B patients
Accepted as oral presentation at the 13th Annual ITNS Symposium and General Assembly. October 14-16, 2004 Vancouver, BC Canada.
Accepted as poster presentation at the 13th Annual ITNS Symposium and General Assembly October 14-16, 2004 Vancouver, BC Canada.
Should living donor liver graft be considered for retransplantation for recurrent hepatitis C. Should living donor liver graft be considered for retransplantation for recurrent hepatitis C
Accepted as oral presentation at the 13th Annual ITNS Symposium and General Assembly October 14-16, 2004 Vancouver, BC Canada.
Outcome of hepatic retransplantation in hepatitis C viral (HCV) positive subjects versus HCV negative subjects
Accepted as Poster presentation at the 13th Annual ITNS Symposium and General Assembly October 14-16, 2004 Vancouver, BC Canada.
Accepted as oral presentation at the 13th Annual ITNS Symposium and General Assembly. October 14-16, 2004 Vancouver, BC Canada.
Hemochromatosis in male/female requiring liver transplantation and survival outcome
Accepted as oral presentation at the 13th Annual ITNS Symposium and General Assembly, October 14-16, 2004 Vancouver, BC Canada.
Bryan, AB Jain, Adel Bozorgzadeh, Randeep Kashyap, Kerrie Lansing, Mark Kelley, Mark Orloff. Use of lamivudine prophylaxis with short course of hyperimmune hepatitis B immunoglobin (HBIG) for hepaptitis B core antibody (HbcAB) positive liver allograft recipients who are hepatitis B surface antibody (HbsAB) and hepatitis B surface antigen (HbsAg) negative
Accepted as poster presentation at the 13th Annual ITNS Symposium and General Assembly, October 14-16, 2004 Vancouver, BC Canada.
changes in oral absorption of tacrolimus in post liver transplant patients before and after reversal of jejunal ileal (J-I) bypass: Case reports
Accepted as poster presentation at the 13th Annual ITNS Symposium and General Assembly. October 14-16, 2004 Vancouver, BC Canada.
Accepted as oral presentation at the 13th Annual ITNS Symposium and General Assembly. October 14-16, 2004 Vancouver, BC Canada
Milot, Adel Bozorgzadeh , AB Jain, Charlotte Ryan , Daniel Orndt , Martin Zand , Parvez Mantry , Kerrie Lansing and Mark Orloff Living donor allograft versus cadaveric liver allograft for hepatitis C viral infection in 100 consecutive liver transplant recipients under tacrolimus: Single Center Experience
Accepted as poster presentation at the 13th Annual ITNS Symposium and General Assembly October 14-16, 2004 Vancouver, BC Canada.
Accepted as oral presentation at the 13th Annual ITNS Symposium and General Assembly. October 14-16, 2004 Vancouver, BC Canada.
Johnson, Adel Bozorgzadeh , AB Jain, Randeep Kashyap , Kerrie Lansing and Mark Orloff Survival outcome for hepatitis C recipients who received hepatitis B core antibody positive liver allograft
Accepted as oral presentation at the 13th Annual ITNS Symposium and General Assembly October 14-16, 2004 Vancouver, BC Canada.
Accepted as oral presentation at the 13th Annual ITNS Symposium and General Assembly. October 14-16, 2004 Vancouver, BC Canada.
Accepted as Poster presentation at the American Transplant Congress May 14-19, 2004 Boston, MA.
Marcos1, R. Kashyap 2 G. Mazariegos1.Bijan Eghtesad1, W. Marsh1, P. Fonte1s, M
DeVera1, J Fung1 Surgical/Non Surgical, Immunological/Non Immunological, Early and Late complications after primary Liver Transplantation and its impact on graft and patient survival in adults and children. An analysis of 1000 consecutive patients with 9-12 years follow-up. Accepted as Poster presentation at the American Transplant Congress May 14-19, 2004 Boston, MA
Orloff, Adel Bozorgzadeh, Kerrie E. Lansing, Jackie Cullen, Charlotte Ryan, AB Jain, David Waldman. Post- operative liver dysfunction following donations of segmental liver graft
American Journal of Transplantation 2004, Supp 8: Vol 4, P 532, Abstract # 1364.
Valgan (ganciclovir hydrochloride) provides ineffective prophylaxis against cytomegaloviral (CMV) infection in liver transplant recipients
American Transplant Congress, May 15-19, 2004, Boston, Massachusetts, Abstract# 1499, American Journal of Transplantation Vol. 4. Supplement 8; pp.569.
Changes in oral absorption of tacrolimus post liver transplant patients before and after reversal of jejunal ileal (J-I) bypass: case reports
ILTS Annual Meeting, June 9-12, 2004, Kyoto, Japan, Abstract# 19, Liver Transplantation 10:6, June 2004.
Survival outcome after retransplantation for recurrent hepatitis c viral (HCV) infection
ILTS Annual Meeting, June 9-12, 2004, Kyoto, Japan, Abstract# 21, Liver Transplantation 10:6, June 2004.
Hemachromatosis in male / female requiring liver transplantation and survival outcome
ILTS Annual Meeting, June 9-12, 2004, Kyoto, Japan, Abstract# 22, Liver Transplantation 10:6, June 2004.
Outcome of hepatic retransplantation in hepatitis c viral (HCV) positive subjects versus HCV negative subjects
ILTS Annual Meeting, June 9-12, 2004, Kyoto, Japan, Abstract# 65, Liver Transplantation 10:6, June 2004.
High rate of symptomatic cytomegaloviral (CMV) infection with valgan (ganciclovir hydrochloride) prophylaxis in post liver transplant recipients
ILTS Annual Meeting, June 9-12, 2004, Kyoto, Japan, Abstract# 77, Liver Transplantation 10:6, June 2004.
Should living donor liver graft be considered for retransplantation for recurrent hepatitis c?
ILTS Annual Meeting, June 9-12, 2004, Kyoto, Japan, Abstract# 105, Liver Transplantation 10:6, June 2004.
Impact of donor evaluation factors on post operative liver function in adult-to-adult living liver donation: a retrospective multivariate analysis to establish donor safety criteria
ILTS Annual Meeting, June 9-12, 2004, Kyoto, Japan, Abstract# 114, Liver Transplantation 10:6, June 2004.
Use of rapamycin in post liver transplantation (LTX) for nephrotoxicity under calcineurin inhibitor
ILTS Annual Meeting, June 9-12, 2004, Kyoto, Japan, Abstract# 152, Liver Transplantation 10:6, June 2004.
Safety and efficacy profile of pegylated interferon α2B (pegintron)® iv/s pegylated interferon α2A (pegasys)® in post liver transplant (LTx) hepatitis c virus (HCV) genotype 1A/1B patients
ILTS Annual Meeting, June 9-12, 2004, Kyoto, Japan, Abstract# 157, Liver Transplantation 10:6, June 2004.
Liver transplantaion (LTX) for sarcoidosis: question of recurrence
ILTS Annual Meeting, June 9-12, 2004, Kyoto, Japan, Abstract# 158, Liver Transplantation 10:6, June 2004.
Impact of older donor grafts in liver transplant (LTx) recipients with hepatitis c viral (HCV) infection
ILTS Annual Meeting, June 9-12, 2004, Kyoto, Japan, Abstract# 161, Liver Transplantation 10:6, June 2004.
Living donor allograft versus cadaveric liver allograft for hepatitis c viral infection in 100 consecutive liver transplant recipients under tacrolimus: single center experience
ILTS Annual Meeting, June 9-12, 2004, Kyoto, Japan, Abstract# 162, Liver Transplantation 10:6, June 2004.
Survival outcome for hepatitis c recipients who received hepatitis b core antibody positive liver allograft
ILTS Annual Meeting, June 9-12, 2004, Kyoto, Japan, Abstract# 163, Liver Transplantation 10:6, June 2004. Adel Bozorgzadeh. Ashok Jain, Kerrie Lansing, Randeep Kashyap, M. Orloff Impact of donor age in live donor liver transplantation for hepatitis C positive recipient.Accepted as Poster presentation at 2nd International Conference entitled “Living Donor Abdominal Organ Transplantation: State of the Art” in Taormina, Sicily, Italy on June 25-27, 2004
Orloff, Randeep Kashyap, Adel Bozorgzadeh
Use Of Intravenous (Iv) Mycophenolate Mofetil (Mmf) And Delayed Introduction Of Low Dose Oral Tacrolimus To Preserve Renal Function In Living Donor Liver Transplantation. Accepted as Poster presentation at 2nd International Conference entitled “Living Donor Abdominal Organ Transplantation: State of the Art” in Taormina, Sicily, Italy on June 25-27, 2004
Adel Bozorgzadeh , Ashokkumar Jain, Charlotte Ryan , Daniel Orndt , Martin Zand , Parvez Mantry , Kerrie Lansing and Mark Orloff Living Donor Allograft Versus Cadaveric Liver Allograft For Hepatitis C Viral Infection In 100 Consecutive Liver Transplant Recipients Under Tacrolimus: Single Center Experience. Accepted as oral presentation at 2nd International Conference entitled “Living Donor Abdominal Organ Transplantation: State of the Art” in Taormina, Sicily, Italy on June 25-27, 2004
Jackie Cullen, Ashokkumar Jain, Mark Orloff , Randeep Kashyap , Kerrie Lansing and Adel Bozorgzadeh Should Living Donor Liver Graft Be Considered For Retransplantation For Recurrent Hepatitis C. Accepted as Poster presentation at 2nd International Conference entitled “Living Donor Abdominal Organ Transplantation: State of the Art” in Taormina, Sicily, Italy on June 25-27, 2004
Recurrence Of Hepatocellualr Carcinoma (Hcc) In Live Donor Liver Tranplantation Vs
Cadeveric Liver Transplantation In Relation To Staging Ofthe Disease Accepted as Poster presentation at 2nd International Conference entitled “Living Donor Abdominal Organ Transplantation: State of the Art” in Taormina, Sicily, Italy on June 25-27, 2004
Bozorgzadeh A, Jain A, Kashyap R, Lansing K, Abt P, Orloff M. Impact of Older Donor Grafts in Liver Transplant (LTx) recepients with Hepatitis C viral (HCV) infection in IXth Congress of the Middle East Society of Organ Transplantation (MESOT) on December 6-10, Turkey
Survival outcome for hepatitis c recipients who received hepatitis B core antibody positive liver allograft
IXth Congress of the Middle East Society of Organ Transplantation (MESOT) on December 6-10, Turkey
Survival outcome after retransplantation for recurrent hepatitis C viral (HCV) infection
IXth Congress of the Middle East Society of Organ Transplantation (MESOT) on December 6-10, Turkey
Changes in oral absorption of tacrolimus in post liver transplant patients before and after reversal of jejunal ileal(j-i) bypass: case reports
IXth Congress of the Middle East Society of Organ Transplantation (MESOT) on December 6-10, Turkey
High rate of symptomatic cytomegaloviral (cmv) infection with valgan (ganciclovir hydrochloride) prophylaxis in post liver transplant recipients
IXth Congress of the Middle East Society of Organ Transplantation (MESOT) on December 6-10, Turkey
Value of ribavirin concentration measurement in plasma/blood in post liver transplant patients with hepatitis c virus (hcv) infection
IXth Congress of the Middle East Society of Organ Transplantation (MESOT) on December 6-10, Turkey
A Jain, M Giraldo, R Pokharna, J Fung, A Marcos Outcome of Liver Transplantation for Hemophiliacs and HCV, with or without HBV & HIV infection under Tacrolimus – Nine Years Experience from a single Centre Transplant Asia 2004, 1st – 4th December, 2004, Singapore
Ashokkumar Jain, Mark Orloff, Randeep Kashyap, Kerrie Lansing, Roberts Betts, Merelyn Menegus, Charlotte Ryan, Peter Abt, Adel Bozorgzadeh Does Valganciclovir Hydrochloride (Valcyte TM) Provide Effective Prophylaxis against Cytomegalovirus (CMV) Infection in Liver Transplant Recepients? Transplant Asia 2004, 1st – 4th December, 2004, Singapore
Ashok Jain, Renu Pokharna, Kareem Abu-Elmagd, Randeep Kashyap, Ron Shapiro, Velma Scantlebury, Bijan Eghtesad, Paulo Fontes, Mary Gadornski, amadeo Marcos, John Fung Use of Rituximab (Chimeric Anti-CD20 Antibody) in Post Transplant Lymphoproliferative Disorder (PTLD) after Liver, Kidney and Pancreas Transplantation Transplant Asia 2004, 1st – 4th December, 2004, Singapore
Randeep Kashyap, Ashok Jain, Renu Pokharna, Kareem Abu-Elmagd, Ron Shapiro, Velma Scantlebury, Bijan Eghtesad, Paulo Fontes, Mary Gadornski, Amadeo Marcos, John Fung Impact of Cytomegalovirus (CMV) Hepatitis in Adult Post Transplant Allograft under Tacrolimus Transplant Asia 2004, 1st – 4th December, 2004, Singapore
A Jain, M Orloff, R Kashyap, B Kari, A Bozorgzadeh. Use of Intravenous Mycophenolate Mofetil and delated us of Tacrolimus in Deceased Donor Liver Transplantation to preserve Renal function Transplant Asia 2004, 1st – 4th December, 2004, Singapore
G Costa, Ashokkumar Jain, Amadio Marcos, Jorge Reyes, George Mazariegos, R Kashyap, John J Fung Incidence of Bile Duct complications following Primary Liver Transplantation in Adults and Children: 1000 consecutive patients Transplant Asia 2004, 1st – 4th December, 2004, Singapore
Ashokkumar B Jain, G costa, Arnadio Marcos, Jorge Reyes, George Mazariegos, S Jorge Rakela, John J Fung Rate of Hepatic Artery Complicatons following Primary Liver Transplantation in Adults and Children: 1000 consecutive cases under Tacrolimus Transplant Asia 2004, 1st – 4th December, 2004, Singapore.
Preliminary result on hepatitis c viral (HCV) antibody titre in relation to hepatitis c viral load, hepatic injury and response to anti-HCV treatment in post liver transplant (LTx) patients
American Association for the Study of Liver Diseases – Hepatitis Single Topic Conference “Hepatitis C Virus Infection: Pathobiology and Implications for New Therapeutic Options” 4th – 5th March, 2005, Chicago, Illinois Ashokkumar Jain, Mark Orloff, Peter Abt, Ravi Mohanka, Randeep Kashyap, Kerrie Lansing, Joan Romano, Adel Bozorgzadeh. Survival outcome after hepatic retransplantation for hepatitis C viral positive and negative recipients. American Association for the Study of Liver Diseases – Hepatitis Single Topic Conference “Hepatitis C Virus Infection: Pathobiology and Implications for New Therapeutic Options” 4th – 5th March, 2005, Chicago, Illinois Ashokkumar Jain, Mark Orloff, Peter Abt, Ravi Mohanka, Randeep Kashyap, Kerrie Lansing, Joan Romano, Adel Bozorgzadeh. Safety & efficacy of pegylated interferon alfa 2b vs pegylated interferon alfa 2a in post liver transplant (LTx) hepatitis C viral (HCV) genotype 1A/1B patients. American Association for the Study of Liver Diseases – Hepatitis Single Topic Conference “Hepatitis C Virus Infection: Pathobiology and Implications for New Therapeutic Options” 4th – 5th March, 2005, Chicago, Illinois
Ribavirin levels in post liver transplant (LTx) patients treated for recurrent hepatitis c viral (HCV) infection
American Association for the Study of Liver Diseases – Hepatitis Single Topic Conference “Hepatitis C Virus Infection: Pathobiology and Implications for New Therapeutic Options” 4th – 5th March, 2005, Chicago, Illinois
Hepatitis C virus (HCV) infected Liver transplant (LTx) recipients with Hepatocellular carcinoma (HCC): survival outcome
American Association for the Study of Liver Diseases – Hepatitis Single Topic Conference “Hepatitis C Virus Infection: Pathobiology and Implications for New Therapeutic Options” 4th – 5th March, 2005, Chicago, Illinois
Hepatitis C virus (HCV) patients co-infected with cytomegalovirus (CMV) infection in post Liver transplant (LTx): impact on survival
American Association for the Study of Liver Diseases – Hepatitis Single Topic Conference “Hepatitis C Virus Infection: Pathobiology and Implications for New Therapeutic Options” 4th – 5th March, 2005, Chicago, Illinois Jain A, Eghtesad B, Broznick B, Kusum P, Sayeed M, Thomas C, De Vera ME, Fontes PA, Gayowski T, Marsh W, Marcos A, Fung J. University of Wisconsin (UW) versus histidine-tryptophan-ketoglutarate (HTK) for tissue preservation in live donor liver transplantation. American Transplant Congress (ATC) May 21st – 25th 2005, Seattle, WA
Survival outcomes in hepatitis C (HCV) infected liver transplant (LTx) recipients with hepatocellular carcinoma (HCC)
American Transplant Congress (ATC) May 21st – 25th 2005, Seattle, WA
(put other authors) Survival outcomes in hepatitis C (HCV) infected liver transplant (LTx) recipients with hepatocellular carcinoma (HCC)
11th International Liver Transplant Society (ILTS) Annual Meeting, July 20-23, 2005, Losangeles, CA, USA.
(put other authors) Risk factors and implications of vancomycin resistant enterococcus (VRE) in liver transplant recipients
11th International Liver Transplant Society (ILTS) Annual Meeting, July 20-23, 2005, Losangeles, CA, USA.
Post liver transplant (LTx) hepatitis C viral (HCV) antibody titre in relation to hepatitis C viral load, hepatic injury and response to anti-HCV treatment – preliminary results
11th International Liver Transplant Society (ILTS) Annual Meeting, July 20-23, 2005, Losangeles, CA, USA.
University of Wisconsin (UW) versus Histidine-Tryptophan-Ketoglutarate (HTK) for tissue preservation in live donor liver transplantation
11th International Liver Transplant Society (ILTS) Annual Meeting, July 20-23, 2005, Losangeles, CA, USA.
Intra operative biochemical changes in live donor liver transplantation at the end of parenchymal division
11th International Liver Transplant Society (ILTS) Annual Meeting, July 20-23, 2005, Losangeles, CA, USA.
Jain, M. Orloff, R Mohanka, R. Kashyap, M Kelley, B.Kari, A. Bozorgzadeh. Intravenous mycophenolate mofetil and delayed use of tacrolimus in deceased and live donor liver transplantation for preservation of renal function
11th International Liver Transplant Society (ILTS) Annual Meeting, July 20-23, 2005, Losangeles, CA, USA.
Intravenous mycophenolate mofetil and delayed use of tacrolimus in deceased and live donor liver transplantation for preservation of renal function
14th Annual ITNS Symposium and General Assembly. September 22-24, 2005 • Orlando, Florida USA
Post liver transplant (LTx) hepatitis c viral (HCV) antibody titre in relation to hepatitis c viral load, hepatic injury and response to anti-hcv treatment preliminary results
14th Annual ITNS Symposium and General Assembly. September 22-24, 2005 • Orlando, Florida USA
Tacrolimus for primary liver transplantation; 12 to 15 years actual follow up with safety profile
14th Annual ITNS Symposium and General Assembly. September 22-24, 2005 • Orlando, Florida USA
Intra operative biochemical changes in live donor liver transplantation at the end of parenchymal division
14th Annual ITNS Symposium and General Assembly. September 22-24, 2005 • Orlando, Florida USA
University of Wisconsin (UW) versus Histidine-Tryptophan-Ketoglutarate (HTK) for tissue preservation in live donor liver transplantation
14th Annual ITNS Symposium and General Assembly. September 22-24, 2005 • Orlando, Florida USA
Outocme of late stage Hepatocellular carcinoma (HCC) in those outside of Milan / Univesrity of California, San Francisco (UCSF) criteria: results of a single centre study
14th Annual ITNS Symposium and General Assembly. September 22-24, 2005 • Orlando, Florida USA
Outcome of Hepatitis C patients co-infected with cytomegalovirus (CMV) post liver transplant (LTx)
14th Annual ITNS Symposium and General Assembly. September 22-24, 2005 • Orlando, Florida USA
Survival & outcomes in Hepatits C (HCV) infected liver transplant (LTx) recipients with hepatocellular carcinoma (HCC)
14th Annual ITNS Symposium and General Assembly. September 22-24, 2005 • Orlando, Florida USA
Risk factors and implications of Vancomycin Resistant Enterococcus (VRE) in liver transplant recipients
14th Annual ITNS Symposium and General Assembly. September 22-24, 2005 • Orlando, Florida USA
Survival & Outcomes in Hepatitis C (HCV) infected liver transplant (LTx) recipients with hepatocellular carcinoma (HCC)
11th Annual meeting of the International Liver Transplant Society (ILTS) July 21-24, 2005. Los angeles, CA, USA
Hepatic artery stenosis in orthotopic liver transplantation (LTx): single centre experience in a series of 527 patients
11th Annual meeting of the International Liver Transplant Society (ILTS) July 21-24, 2005. Los angeles, CA, USA
University of Wisconsin (UW) versus Histidine-Tryptophan-Ketoglutarate (HTK) for tissue preservation in live donor liver transplantation
11th Annual meeting of the International Liver Transplant Society (ILTS) July 21-24, 2005. Los angeles, CA, USA
An association between healthcare utilization and outcomes in the MELD era
11th Annual meeting of the International Liver Transplant Society (ILTS) July 21-24, 2005. Los angeles, CA, USA
Optimal use of extended criteria organds in the MELD era
11th Annual meeting of the International Liver Transplant Society (ILTS) July 21-24, 2005. Los angeles, CA, USA
Risk factors and inplicaitons of Vanclmycin resistant enterococcus (VRE) in liver transplant recipients
11th Annual meeting of the International Liver Transplant Society (ILTS) July 21-24, 2005. Los angeles, CA, USA
11th Annual meeting of the International Liver Transplant Society (ILTS) July 21-24, 2005. Los angeles, CA, USA
An association of pre-transplant HCV associated cryoglobulinemia (CRG) with post-liver transplant survival outcomes
11th Annual meeting of the International Liver Transplant Society (ILTS) July 21-24, 2005. Los angeles, CA, USA
Outcome of hepatitis C patients co-infected with cytomegalovirus (CMV) infection post-liver transplant (LTx)
11th Annual meeting of the International Liver Transplant Society (ILTS) July 21-24, 2005. Los angeles, CA, USA
Donor/Recipient cytomegalovirus (CMV) status and its influence on hepatic artery thrombosis (HAT) post-liver transplantation (LTx)
11th Annual meeting of the International Liver Transplant Society (ILTS) July 21-24, 2005. Los angeles, CA, USA
Intravenous mycophenolate mofetil and delayed use of tacrolimus in deceased and live donor liver transplantation for preservation of renal function
11th Annual meeting of the International Liver Transplant Society (ILTS) July 21-24, 2005. Los angeles, CA, USA
Liver transplantation from non-heart beating donor (NHBD) – a single centre experience
11th Annual meeting of the International Liver Transplant Society (ILTS) July 21-24, 2005. Los angeles, CA, USA
Outcome of late stage hepatocellular carcinoma (HCC) those outside Milan / University of California, San Francisco (UCSF) criteria: results of a single centre study
11th Annual meeting of the International Liver Transplant Society (ILTS) July 21-24, 2005. Los angeles, CA, USA
Intra-operative biochemical changes in live donor liver transplantation at the end of parencymal division
11th Annual meeting of the International Liver Transplant Society (ILTS) July 21-24, 2005. Los angeles, CA, USA.
Intraoperative biochemical changes in live donor liver transplantation at the end of parenchymal division and its post-operative impact
12th Congress of the European Society for Organ Transplantation (ESOT) 15th – 19th October 2005, Geneva, Switzerland
Intravenous mycophenolate mofetil and delayed use of tacrolimus in deceased and live donor liver transplantation for preservation of renal function
12th Congress of the European Society for Organ Transplantation (ESOT) 15th – 19th October 2005, Geneva, Switzerland
Ashok Jain, Marilyn Menegus, Ravi Mohanka, Mark Orloff, Peter Abt, Adel Bozorgzadeh. HCV antibody quantitative levels in post-liver transplant patients: do they have any relevance in clinical practice? 12th Congress of the European Society for Organ Transplantation (ESOT) 15th – 19th October 2005, Geneva, Switzerland
University of Wisconsin (UW) versus Histidine – Tryptophan – Ketoglutarate (HTK) for tissue preservation in live donor liver transplantation
12th Congress of the European Society for Organ Transplantation (ESOT) 15th – 19th October 2005, Geneva, Switzerland
Use of complement C4d stain to distinguish between acute cellular rejection and recurrent hepatitis C in post liver transplant liver biopsy
56th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). November 11 – 15, 2005. San Francisco, California, USA
Kinetics observation of IV Mycophenolate mofetil (MMF) and oral MMF in live donor and diseased donor liver transplantation (LTx)
56th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). November 11 – 15, 2005. San Francisco, California, USA.
Non-alcoholic Substance Abuse in Liver Transplant Patients and its Impact on Survival Outcome
56th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). November 11 – 15, 2005. San Francisco, California, USA.